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This project is focused on the synthesis and biologcal activity of aloin and derivatives.  Aloin 
is a C-glucoside anthrone that is found in Aloe marlothii, a common Southern African plant 
used in traditional medicine.  Aloin was isolated from A. marlothii, employing a selective 
chelation isolation procedure.  This compound is know  to have numerous biologically active 
properties, and can be used as a laxative, an anti-b cterial agent, an anti-oxidant, and as a 
cytotoxic drug against breast and ovarian tumour cell lines.  More relevant to this research 
investigation, was the reported anti-inflammatory activity of aloin.  Specifically, the inhibitory 
activity of aloin on matrix metalloproteinases, which when excessively secreted, can lead to 
the development of osteoarthritis and cancer metastasis.  Aloin has also been reported to have 
antiplasmodial activity, which was also investigated.   
 
Aloin was synthetically transformed into several derivatives, which could be potentially useful 
medicinal compounds.  The choice of derivatives to be made was based upon (i) known 
biologically active compounds (e.g. aloe-emodin) and (ii) interesting biologically active 
functional groups (e.g. amines). These aloin derivatives include aloe-emodin, rheinal, rhein 
and three amine derivatives.  Homonataloin, an aloin-analogue, which was also isolated from 
A. marlothii, was synthetically transformed into nataloe-emodin.   These two compounds serve 
as aloin structural analogues for the biological testing.  Aloin and derivatives were 
characterised using NMR, HR-MS, UV and IR, which allowed for their unambiguous 
structural elucidation.    
 
Aloin and derivatives were all tested for (i) possible inhibition towards MMP-2 and MMP-9, 
which are the two most common MMPs in the blood, and (ii) antiplasmodial activity against 
chloroquine sensitive Plasmodium falciparum parasites.  Doxycycline, a clinical tetracycline 
drug, was used as a reference compound for the biological assays, since it shares many 
common structural features with aloin and derivatives. 11-(Piperidin-1-yl)chrysophanol  and 
11-(morpholin-1-yl)chrysophanol proved to be the most potent selective MMP-2 inhibitors.  
11-(Piperidin-1-yl)chrysophanol was also found to be the most potent against P. falciparum 
parasite, along with 11-(pyrrolidin-1-yl)chrysophanol. 
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Aloin has been shown to be a cheap, easily obtainable lead compound that could facilitate the 
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The total synthesis of medicinally useful compounds is a highly daunting and challenging 
task.  This requires both high skills levels and financial capital outlay.  The goal of 
obtaining a medicinally valuable compound by partial synthesis, starting from a readily 
available starting material is an extremely attractive one.  Such a compound may be aloin 
(1.1), which is a naturally occurring C-glucoside anthrone that has been reported to have 
many potentially useful biological properties1.  The most interesting biological activity of 
aloin (1.1) is the reported non-competitive inhibitory action against the extracellular 
matrix-degrading enzyme, metalloproteinase-82.  Metalloproteinase-8 belongs to a family 
of enzymes called matrix metalloproteinases (MMPs).  These enzymes are finely regulated 
at three stages, but sometimes, this control is altered or lost.  The result is excessive tissue 
breakdown at an unbalanced replacement build-up rate, leading to medical conditions such 
as osteoarthritis, tumour growth and metastasis, and periodontal disease3.  The in vitro 
antiplasmodial activity of aloin (1.1) against the chloroquine-resistant Plasmodium 
falciparum strain has also been reported, with an IC50 value of 107.20 ± 4.14 µg ml
-1 4.  
Aloin (1.1) is found in moderate amounts in the leaf exudate of two common, robust, 
easily-cultivatable Aloe plants, i.e. Aloe marlothii A.Berger subsp. marlothii and Aloe ferox 
Mill.  Thus, aloin (1.1) is a natural product with commercial potential that can be obtained 
from a cheap, easily obtainable, renewable resource.  The investigation of the biological 














                                                           (1.1) 
1.2 The genus Aloe L. 
 
The genus Aloe comprises approximately 600 species, most of which o cur naturally in 
Sub-Saharan Africa, except for the moist lowland forest regions and the western part of 
West Africa.  Some species are found in the Arabian Pe insula and in Madagascar.  A few 
Aloe species, formerly in the genus Lomatophyllum, are known from some of the smaller 
Indian Ocean islands5. 
 
Aloe plants are perennial, leaf-succulent xerophytes.  Xerophytes are plants adapted to 
survive in areas of low or erratic precipitation, ad these adaptations may include structural 
and physiological features.  One kind of xerophytic adaptation is succulence, which is the 
development of water storage tissue, consisting of large thin-walled cells in which water is 
held in mucilage.  The enlargement of leaves or stem  in Aloe plants is a modification to 
accommodate the water storage tissue.  The leaf cuticle is thick and is covered by a layer of 
wax, which has distinct patterns of ridges and/or micro papillae and sunken stomata.  Many 
Aloe species have groups of cells associated with the vascular bundles, called aloin or 
aloitic cells that store and possibly secrete a mixture of compounds with medicinal value, 
with the composition varying in different species.  The breakage of leaves exposes this 
exudate, normally yellow in colour, strong smelling and bitter in taste1.   
 
The bitter leaf exudates of some Aloe species are of commercial importance.  These serve 
as renewable sources of the laxative aloe drug.  This exudate has also been employed as a 
bittering agent in alcoholic beverages.  Aloe gel is the clear jelly-like substance obtained 
from the leaf pulp.  The mechanical extrusion of the mucilaginous gel from the fibrous 
fraction of the pulp gives a 70% yield with a water content of 99%.  This gel is used in the 
cosmetic industry in shampoos, shaving and skin care reams and in the treatment of skin 
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disorders, especially, as topical medication for the treatment of burns.  Medicinally, the gel 
and dried leaf exudates of Aloe species have been used by ancient civilizations of the 
Egyptians, Greeks and Mediterranean people6. 
 
1.2.1 Aloe marlothii and Aloe ferox 
 
A. marlothii (Fig. 1.1) is a large single-stemmed plant occurring  South Africa, 
Botswana, Mozambique and Zimbabwe7.  A. marlothii was previously commercially 
harvested for the production of the drug ‘aloes’ but this was ceased due to the erratic 
chemical variance of anthrones, i.e. aloin (1.1) and homonataloin (1.2) in the plant.  This 
species is now only utilized in traditional medicine.  This includes the treatment of round-
worm infections, using the powdered dry leaves in snuff, for stomach troubles, and for 
weaning breastfed children by rubbing green leaf pulp over the breasts8.  The leaves of A. 
marlothii are used by communal stock owners in the North West Province of South Africa 
to treat and prevent gallsickness (Anaplasma marginale infection in cattle), to treat 
parasitic helminthiasis, diarrhoea, constipation, general ailments, retained placenta, 
dystocia, to remove maggots from wounds and to reduc  tick burdens9. 
 
         
                  (A) http://en.wikipedia.org/wiki/Image:Aloe_marlothii00 .jpg          (B) http://commons.wikimedia.org/wiki/Image:Aloe_ferox.JPG 
 















A. ferox (Figure 1.1) is the major Aloe species that is commercially used in South Africa.  
It is a plant similar to A. marlothii, both physiologically and in its chemistry.  
Commercially A. ferox is preferred over A. marlothii, due to minimal chemical variance in 
terms of its phenolics1.  A. ferox is found predominantly in the lower western half of S uth 
Africa and is known as the ‘Cape Aloe’.  A. marlothii on the other hand, is found in the 
upper eastern half of South Africa, and prefers more mountainous terrain, and is therefore 
called ‘mountain Aloe’.  There are regions where these plants coexist, and hybridization 
between the two is a very common occurrence10. 
 
1.3 Chemical Constituents of Aloe Species 
 
A variety of secondary metabolites are produced in the leaves and roots of Aloe plants.  
Many different classes of compounds are represented h re including alkaloids, 
anthraquinones, anthrones, bianthraquinoids, chromones, coumarins and pyrones.  The 
most important constituents ofAloe bitters are the anthrones, aloin A (1.3) and B (1.4), and 
the chromones aloesin (1.5) and aloeresin A (1.6)1.  These compounds are all found in the 













































                 
                             (1.5)                                                          (1.6) 
 
1.3.1 Anthrones: Aloin (1.1) 
 
Of all the classes of compounds occurring in Aloe species, anthrones are considered to be 
the most important.  Within this class itself, the most abundant is aloin (1.1), which was 
first isolated from A. arborescens in the 1800’s11.  Aloin consists of a mixture of aloin A 
(1.3) and aloin B (1.4), two diastereomeric C-glucosides that differ in the configuration at 
C-10 of the aloe-emodin anthrone moiety6.  A biosynthetic study carried out by Grún and 
Franz in 1980 has shown that aloin B (1.4) is the true natural product, which is produced 
by the plant and is enzymatically converted to aloin A (1.3)12.  That study also established 
that aloin B (1.4) is formed by attachment of D-glucose to aloe-emodin anthrone, a 
compound detected so far in flowers but not in the leaves of Aloe plants.  In aloin B (1.3), 
the glucose moiety attached to C-10 has the α-orientation (i.e., 10R, 1'S) and conversely, in 
aloin A (1.2), the β-orientation (i.e., 10S, 1'S). 
 
The carbon-carbon bond between the sugar and the anrone (i.e. the bond from C-10 on 
anthrone) is quite resistant to acid and alkaline conditions.  The cleavage of this bond is 
achieved by oxidation, rather than hydrolysis, and o ly under drastic conditions of acid in 
combination with an oxidant.  This bond is also resistant to β-glycosidase of plants and 
most plant bacteria, however, the intestinal microflora of humans and animals have been 
shown to cleave this C-glucosyl bond, although considerable variation in response among 
animal species occurs13. 
 
The percentage of aloin (1.1) in the leaf exudate varies from species to species, from 
season to season, and depends on plant or leaf age.  The aloin (1.1) content of leaf exudate 
from different Aloe species was analysed by numerous methods and was found to be 10-
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25% on a dry weight basis of the leaf exudate12.  A recent chemotaxonomic survey of 380 
species of Aloe showed that aloin is found in 36 (10%) of the species14.  The occurrence of 
aloin is not confined only to Aloe species as it has also been found in the extracts of 
Rhamnus purshiana1. 
 
Homonataloin (1.2) is another anthrone which has a similar structure o that of aloin (1.1).  
Homonataloin (1.2), which also occurs as diastereomers, was found to occur in 47 (12%) 
of 380 Aloe species tested, including A. marlothii14.  The distribution of homonataloin (1.2) 
is more restricted compared to that of aloin (1.1).  The chemical occurrence of aloin (1.1) 
and homonataloin (1.2) has been found to be mutually exclusive in Aloe species, with 
A. mutabilis being a notable exception1.  Thus, within a specific Aloe plant, that is known 
to produce the anthrones, either aloin (1.1) or homonataloin (1.2) may occur, but not both 
simultaneously.  This chemical variance between homonataloin (1.2) and aloin (1.1) in 
A. marlothii was the major factor in stopping the commercial harvesting of the plant.   
 
1.3.2 Biological Activity of Aloin (1.1) 
 
The most well-documented yet mechanistically unknow activity of aloin (1.1) is its 
purgative/laxative action in animals.  Aloin (1.1) has been shown to be metabolized to the 
reactive aloe-emodin (1.7) by the colonic flora (Eubacterium species) in the gut.  It has 
been demonstrated that aloe-emodin (1.7) exerts its action on the colonic mucosa, but its 
mechanism of action is still uncertain.  It is postula ed that aloe-emodin (1.7) acts by 
disturbing the equilibrium between the absorption of water from the intestinal lumen via an 
active sodium transport and the secretion of water into the lumen by a prostaglandin-
dependent mechanism.  Aloe-emodin (1.7) also stimulates the release of platelet-activating 






                                                           (1.7) 
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Other reported biological activities of aloin (1.1) include: the induction of programmed cell 
death (apoptosis) in Jurkat cells16, cytotoxicity against certain breast and ovarian ccer 
cell lines17, the increase in the rate of alcohol oxidation in rats18 and the inhibition of 
histamine release from mast cells19.   
 
Aloin (1.1) has been reported to possess a dose-dependent inhibi ory effect on MMPs.  
Aloin (1.1) has shown good inhibitory activity on both Clostridium histolyticum 
collagenase (ChC) and MMP-8 via a predominantly non-c mpetitive inhibitory 
mechanism.   The inhibitory activity of aloin (1.1) on MMP-8 was comparable to that of 
the modified tetracycline doxycycline (1.8), which is the enzyme’s most powerful known 



















                                    (1.8)                                     (1.1) 
 
The carbonyl oxygen at C-12 and the OH group at C-11 on the doxycyline (1.8) structure 
appear essential for activity.  Comparing the structures of doxycycline (1.8) to the structure 
of aloin (1.1), the carbonyl group at C-9, between the hydroxyls at C-8 and C-1 on the 
anthrone, is consistent with that pharmacophore profile and it seems reasonable to 
postulate that the aloin (1.1) inhibition of the MMPs is due to an interaction similar to that 
between doxycycline (1.8) and MMPs2. 
 
1.3.3 Anthraquinones: Aloe-emodin (1.7) 
 
Aloe-emodin (1.7) is found in both the leaves and roots of many Aloe and Senna species.  
This anthraquinone usually occurs in combination with its glycosides or in a reduced 
(anthrone) form.  The amount of aloe-emodin (1.7) in plants is very low, as it is thought to 
arise through the oxidative decomposition of its glycosides, rather than through direct 
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biosynthesis.  Despite being such a minor constituent of the plants, many studies have 
proven that aloe-emodin (1.7) is the active metabolite of both aloin (1.1) and sennosides13. 
 
1.3.4 Biological Activity of Aloe-emodin (1.7) 
 
The list of the biological properties of aloe-emodin (1.7) increases regularly as more 
studies are carried out on this highly active molecul .   
 
The mechanism of the anti-inflammatory and immunodulatory effects of aloe-emodin (1.7) 
and other anthraquinones are proposed to involve curbing oxidation20.   Many reactive 
oxygen species and free radical-mediated reactions are involved in inflammatory 
responses.  Since anthraquinones such as aloe-emodin (1.7) act as both anti-oxidants and 
radical scavengers, they can combat many of these responses.  Aloe-emodin (1.7) reduces 
the inflammation of lymphocytes and Kupfer cells in the liver.  Pre-treatment of the liver 
with aloe-emodin (1.7) reduces the damage caused by toxic species such as carbon 
tetrachloride20.   
 
Aloe-emodin (1.7) also displays anti-bacterial activity, dose-dependently inhibiting the 
growth of Helicobacter pylori, which is a possible causative agent of gastric cancer20.  
Aloe-emodin (1.7) possesses contradictory activities on cell growth.  It was found to 
stimulate the growth of primary rat hepatocytes and, conversely, was found to have 
apoptosis-inducing effect in human lung squamous cell carcinoma and to selectively 
inhibit neuroectodermal tumour growth in vivo20.   
 
Despite all of these medically-promising biological activities, anthraquinones also have 
harmful effects.  These include genotoxic, mutagenic, and tumour-promoting effects.  Thus 
caution should be exercised with regard to the anthr quinones, and further studies need to 
be carried out to more accurately define the activities of each component20. 
 
1.3.5 Chromones: Aloesin (1.5) and Aloeresin A (1.6) 
 
Aloesin (1.5), which can be regarded as the parent compound of the aloe chromones was 
first described in 1970 by Haynes and coworkers21.  Similarly to aloin (1.1), aloesin (1.5) 
has a C-glucoside sugar.  It should be noted that the carbon-carbon bond connecting the 
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sugar to the aglycone is also difficult to break.  This chromone is widespread throughout 
the genus, occurring in around 40% of species examined14. 
 
 Aloeresin A (1.6) is another common chromone found in many Aloe species and differs 
from aloesin (1.5) by a p-coumaroyl group, which is connected to the C-2’ positi n.  This 
ester bond is considerably more labile than the C-glucoside bond, and can be hydrolysed 
under acidic conditions to afford aloesin (1.5)22.   
 
1.3.6 Biological Activity of Aloesin (1.5) and Aloeresin (1.6) 
 
Both aloesin (1.5) and aloeresin A (1.6) show skin-whitening activity.  These compounds 
display inhibitory activity against the enzyme tyrosinase.  Tyrosinase is a copper-
containing monooxygenase enzyme which catalyses the conversion of tyrosine to dopa, 
dopaquinone and subsequent autopolymerisation to melanin23.  Pigmentation in skin results 
from the synthesis and distribution of melanin22.     
 
1.4 Project Aims 
 
The aims of this investigation were: 
 
1. To develop a procedure to isolate aloin from A. marlothii leaf exudate. 
 
2. To synthesise several aloin derivatives, based on potentially interesting biologically   
active functional groups. 
 
3. To test the potential inhibitory properties of aloin and its synthetic derivatives on 
MMP-2 and MMP-9. 
 
4. To screen aloin and its synthetic derivatives for in v tro antiplasmodial activity 
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Aloin (2.1) has been shown to be a highly biologically active compound.  Its numerous 
biological effects, as mentioned in Chapter 1, have be n attributed to both its electron-rich 
ring system and its chelating ability.  Aloin (2.1) has been reported to inhibit MMPs via a 
non-competitive chelation mechanism1.  This property of aloin (2.1) was investigated in 
this research project.  One of the aims of this project was to synthesise a variety of aloin 
derivatives and to test and compare their potential MMP-2 and MMP-9 inhibitory 
properties.  By analyzing the structure of aloin (2.1) the benzylic hydroxy group at C-11 
presents itself as a region of possible functionalisation for derivative formation.  Aloin 
(2.1) will serve as a useful starting compound with many possibilities for the synthesis of 
derivatives.  Aloin (2.1) occurs in many Aloe species2, yet it is an expensive compound to 
purchase.  The most effective and cost-efficient manner of obtaining aloin (2.1) is to isolate 
it from a plant that contains aloin (2.1) in reasonable amounts, i.e. A. marlothii.  A. 
marlothii also contains two other major compounds in its leaf exudate; aloeresin A (2.2) 
and aloesin (2.3)3.  Besides these chromones, an aloin analogue called homonataloin (2.4) 
is also known to occur4.  The occurrence of aloin (2.1) and homonataloin (2.4) is mutually 
exclusive in A. marlothii plants.  Thus an individual A. marlothii plant may contain either 
aloin (2.1) or homonataloin (2.4), but not both simultaneously.  Homonataloin (2.4) should 
serve as a highly useful compound, having a methoxy group at C-8 compared to a hydroxy 
in aloin (2.1).  This chemical variance could have an interesting effect on its activity.     
 





























                  (2.1)                                  (2.2) R = p-coumaroyl                   (2.4)                                            




Anthraquinones are widely studied compounds having many remarkable properties and 
uses.  Many anthraquinones occur naturally, whilst others are either synthetic or semi-
synthetic.   Examples of different classes of anthraquinones, along with their biological 
activities will be discussed briefly in this chapter to illustrate the importance and 
significance of these compounds. 
 
2.2.1 Natural Anthraquinones 
 
Dynemicin A (2.5) is a structurally interesting compound that has received considerable 
interest over the last 15 years due to its potential anticancer applications5.  This molecule is 
a member of the enediyne family of antibiotics which cause cell death through irreversible 
oxidative strand scissions of DNA.  Dynemicin A (2.5) has not been used as a drug due to 












                                                            (2.5) 
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Chlorocyclinone C (2.6) is a novel anthraquinone compound which has been isolated from 
the mycelium of Streptomyces sp. strain DSM 170456.  This compound has been shown to 
antagonize rosiglitazone-induced peroxisome proliferator-activated receptor gamma 
(PPAR-γ) activation with IC50’s < 0.4 µM in vitro.  PPAR-γ antagonists provide a 











CH3 OH  
                                                                  (2.6) 
 
A pentacyclic anthraquinone compound (2.7) has been isolated from Juglans 
mandshurica7.  This compound efficiently induced apoptosis in HeLa cells (a cancer cell 
line) through a mitochondria dependent pathway and ctivation of the caspase cascade.  





O OH  
 (2.7) 
 
A recent phytochemical study of the fruits of Vismia laurentii resulted in the isolation of 
three structurally related anthraquinones; laurentiquonones A (2.8), B (2.9) and C (2.10)8.  
The combined extracts of these compounds displayed nti-plasmodial activity against the 



























(2.8) (2.9)   R = H 
(2.10) R = OAc 
 
Altersolanol A (2.11), a tetrahydroanthraquinone, showed good cytotoxic activity in vitro 
towards L5178Y mouse lymphoma lines9.  This compound also exhibited antimicrobial 
activity against gram-positive pathogens, i.e. Staphylococcus epidermidis, Staphylococcus 
aureus and Enterococcus faecalis.  It has been discovered that altersolanol A (2.11) acts as 
an electron acceptor in the bacterial membrane and thus inhibits bacterial growth.  This 
bioactive metabolite was isolated from the endophytic fungus Ampelomyces sp. which was 











                                                                 (2.11) 
 
Brasilquinolone C (2.12), a benz[a]anthraquinone antibiotic, was isolated from 
fermentations of Nocardia brasiliensis10.  This compound exhibited antimycobacterial 
activity towards Mycobacterium smegmatis with an MIC value of 12.5 µg ml-1.  Mild 





OCH3 O OH  
                                                       (2.12) 
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The anthracyclinone celasramycin B (2.13) was isolated from an unidentified species of 








                                                                  (2.13) 
 
Mumbaistatin (2.14) has been found to be the most potent natural inhibitor of glucose 6-
phosphate transporter 1 (G6PT1), a key enzyme in the regulation of glucose homeostasis, 
making it an important therapeutic target in type II diabetes11.  Mumbaistatin was isolated 














Natural anthraquinones are valuable medicinal compounds.  These are biosynthesized via 
the polyketide synthase pathway.  Many of these compounds play a crucial role in the fight 
against infectious diseases.   
 
2.2.2 Synthetic Anthraquinones 
 
The anthraquinone (2.15) has exhibited in vitro cytotoxicity against several different 
cancer lines through apoptosis.  Apoptosis has becom  a focus of interest in oncology 







                                                 (2.15) 
 
Mitoxanthrone dihydrochloride (2.16) is an important compound used clinically as an 
anticancer agent.  It is used for treating leukemia, lyphomas, and advanced breast and 
ovarian cancer in combination with other treatment13.  The reaction mechanism of the anti-
tumour activity of anthraquinones is probably multimodal in nature, and studies have 














                                                   (2.16) 
 
The anthracycline antibiotics daunomycin (2.17) and doxorubicin (2.18) are clinically 
effective anti-tumour agents14.  They display good potency and are used commonly in the 

























                                (2.17)                                                           (2.18) 
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Synthetic anthraquinones, that are used medicinally, re usually less structurally complex 
than the naturally occurring ones.  Many synthetic anthraquinones are created from a lead 
compound, which is commonly a natural product.   
 
2.2.3 Semi-Synthetic Anthraquinones 
 
Emodin (2.19) and chrysophanol (2.20) are naturally occurring anthraquinones that have 
been used as starting materials for synthesis.  These compounds were isolated from crude 
rhubarb extract.  Their structural aromatic features indicate that these compounds and their 
derivatives (especially positively charged ones) may intercalate into the double helix of 
DNA15.  Libraries of their derivatives were prepared forst ucture-activity relationship 
studies of anticancer activity against mouse leukemia L1210 and human leukemia HL-60 
cells.  In general, it was also reported that anthraquinones bearing an amino function 
interact with DNA.  There was no straightforward correlation apparent between the 
derivative affinity for DNA and their cytotoxic effects.  This study concluded that the 
cytotoxicity produced by these derivatives is time dependent and is not a direct result of 









                                            (2.19)                                              (2.20) 
 
The use of semi-synthetic anthraquinones as potential medicinal drugs is becoming more 
common.  It is often quicker and cheaper to synthetically modify an existing anthraquinone 








2.3 Isolation of A. marlothii Leaf Exudate Compounds 
 
2.3.1 Isolation of Aloin (2.1) and Homonataloin (2.4)  
 
It is well documented that the levels of aloin (2.1) within Aloe species varies from species 
to species, seasonally, and relative to the environmental conditions of the specific Aloe 
plant3.  Thus it is rather difficult to obtain a source of A. marlothii leaf exudate that has 
consistently high aloin (2.1) content.  Furthermore, without TLC pre-analysis of the A. 
marlothii plants’ chemical constituents, it is impossible to determine whether the plant 
contains either aloin (2.1) or homonataloin (2.4).  The A. marlothii sample which was 
obtained in Ladysmith, was a collection of different plants and as expected contained both 
aloin (2.1) and homonataloin (2.4).  This was a beneficial complication as it provided us 
with a source of both aloin (2.1) and homonataloin (2.4), which have sufficiently different 
Rf values on TLC to allow for separation by column chromatography. 
 
2.3.2 Column Chromatography of A. marlothii Leaf Exudate 
 
The Aloe leaf exudate was freeze-dried and then fractionated by column chromatography 
employing a solvent system containing ethyl acetate, m thanol and water in a 77:13:10 
ratio16.  This tried and tested eluent system gives optimal separation of leaf components.  
Thus, this chromatography technique was utilized on the acquired A. marlothii leaf exudate 
sample, resulting in good separation of the sample components.  The order of elution of the 
compounds was: homonataloin (2.4) (Rf = 0.75), aloeresin A (2.2) (Rf = 0.65), aloin (2.1) 
(Rf = 0.58) and then aloesin (2.3) (Rf = 0.38).  However, one major problem with this 
system was that water was present in each fraction.  The only procedure to remove water 
other than freeze-drying is by the addition of toluene.  Toluene forms a stable azeotrope 
with water, thus allowing for easier removal.  High temperatures (boiling point of toluene 
is 110 oC) are required for the solvent removal, which risks the degradation of the isolated 
products.  Thus it was necessary that a more volatile solvent system be developed.  This 
was achieved by replacement of the water with another polar solvent, acetonitrile, which 
has a boiling point of 81 oC.  It was discovered that a 75:10:2 ratio of ethyl acetate 
(EtOAc), methanol (MeOH) and acetonitrile (CH3CN) afforded a degree of separation 
highly comparable to that of the mixture containing water. 
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2.3.3 Structural Confirmation of Aloin A (2.21) 
 
The 1H NMR spectrum (Plate 1a) had peaks characteristic of an aromatic compound with 
an attached sugar.  The aromatic region has five protons, i.e., H-7 (δH 6.68, d, J = 8.6 Hz), 
H-2 (δH 6.78, d, J = 1.5 Hz), H-5 (δH 6.94, d, J = 1.5 Hz), H-4 (δH 7.04, d, J = 8.6 Hz), H-
6( δH 7.47 (1H, t, J = 7.9), which are expected for aloin (2.1).  The splitting pattern of the 
proton attached to C-10 (δH 4.69, d, J = 2.4 Hz) confirmed a C-glucosidic linkage.  The 
signals for the sugar protons H-5’ (δH 2.84, m), H-4’ (δH 2.85, t, J = 9.2 Hz), H-2’ (δH 2.96, 
t, J = 9.2 Hz), H-3’ (δH 3.28, t, J = 9.2 Hz), H-6’b (δH 3.33, m), H-1’ (δH 3.33, t, J = 9.2 
Hz) and H-6’a (δH 3.44, m) are well resolved and allow for unambiguous assignment.  The 
methylene proton H-11 (δH 4.56, d) shift corresponds to that of a benzylic primary alcohol.  
The phenolic hydroxy protons 8-OH (δH 11.35, br s, D2O exchangeable) and 1-OH (δH 
11.68, br s, D2O exchangeable) of aloin (2.1) can also be clearly seen. 
 
The 13C NMR spectrum (Plate 1b) displayed a total of 21 carbon atoms.  Two CH2 
carbons, eleven CH carbons and nine non-protonated carbons were identified.  In the 13C 
NMR spectrum, six signals (δC 63.3, 71.8, 72.0, 80.0, 81.6, 86.6) were characteristic of a 
C-glucose moiety, five aromatic signals (δC 114.4, 116.8, 119.1, 120.0, 137.0,), four 
signals (δC 117.7, 118.7, 143.2, 146.6) and a signal depicting a benzylic methylene group 
(δC 64.5).  Two signals characteristic of phenolic carbons (δC 162.9, 163.4) and one of a 
ketone (δC 195.5) are also observed.   
 
The DEPT 135 spectrum (Plate 1c) corresponded to the 13C spectrum, confirming the 
identity of the two CH2 groups as well as that of the nine CH carbons.  The HSQC 
experiment (Plate 1e) allowed for the correlation of all protonated carbon atoms with well-
resolved protons.  An HMBC experiment (Plate 1f) showed connections of C-8a with H-7 
and H-5, of C-1a with 2-H and 4-H, and of C-3 with 11-H2.   
 
It was interesting to note that only aloin A (2.21) was isolated from the leaf exudate, and 
not a mixture of both the aloin A (2.21) and aloin B (2.22) diastereomers as expected.  The 
acquired NMR data corresponds with the 1H and 13C NMR assignments of aloin A (2.21) 
























                                         (2.21)                                 (2.22) 
 
2.3.4 Structural Elucidation of Homonataloin (2.4) 
 
The 1H NMR spectrum (Plate 4a) of homonataloin (2.4) displays a mixture of two 
compounds, i.e. homonataloin A (2.23) and homonataloin B (2.24) in a 4:1 ratio.  The 
aromatic region depicts four protons for each diastereomer.  For homonataloin A (2.23) 
these are singlets for protons H-2, H-4 (δH 6.62 and 6.76) and doublets for protons H-5 and 
H-6 (δH 7.08 and 7.13).  Similarly for homonataloin B (2.24) H-2 and H-4 (δH 6.65 and 
6.84) are singlets and H-5 and H-6 (δH 7.12 and 7.09) are doublets.  The sugar protons 
resonate in a region (δH 2.6-4.5) similar to those of the sugar in the 
1H NMR spectrum 
aloin A (Plate 1a), both being C-glucosides.  The 11-methyl group (δH 2.29) and methoxy 
group (δH 3.74) clearly differentiate the 
1H NMR spectrum of homonataloin (2.23) from 
that of aloin A (2.21) (Plate 1a).  The shift of the 1-hydroxy proton (δH 12.1) is similar to 
that of aloin A (2.21) (Plate 1a), whilst the hydroxy at H-7 (δH 9.55) is not observed in the 

























                                               (2.23)                                 (2.24) 
 
The 13C NMR spectrum (Plate 4b) displayed a total of 16 carbons for each homonataloin 
diastereomer, one more than that of aloin A (Plate 1 ).  One CH2 carbon, one CH3 carbon, 
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ten CH carbons and nine non-protonated carbons were id ntified.  In the 13C NMR 
spectrum, six signals (δC 60.0-85.0) were characteristic of a C-glucose moiety, four 
aromatic signals (δC 115.6, 119.2, 121.9, 123.8) four quaternary signals (δC 118.0, 127.4, 
136.2, 140.8) and a signal depicting a benzylic methyl group (δC 21.9).  Three signals 
characteristic of phenolic carbons (δC 145.2, 147.5, 160.4) and one of a ketone (δC 190.1) 
were also observed.   
 
The DEPT 135 spectrum (Plate 1c) corresponded to the 13C NMR spectrum, confirming 
the identity of the single CH2 and CH3 groups as well as that of the ten CH carbons.  The
methoxy group is also observed.  A HSQC experiment (Plate 4e) allowed for the 
correlation of all protonated carbon atoms with well-r solved protons.   
 
The 13C NMR shifts of the sugar carbon atoms C-3’, C-5’ and C-1’ were observed at δC 
78.4, 80.4 and δC 84.2 respectively. The assignments of these 
13C NMR signals were not in 
accordance with the assignments reported J. M. Conner et al18, which were deemed 
incorrect. 
 
2.3.5 Selective Calcium Precipitation of Aloin (2.1) 
 
Column chromatography is an effective yet a long and tedious technique for the isolation 
of aloin (2.1).  It was mentioned in an article by Hay and Haynes19 that aloin (2.1) could be 
precipitated from the leaf exudate by the addition of excess calcium salt and ammonium 
hydroxide.  It was proposed that aloin (2.1) formed a calcium salt which precipitated out of 
solution.  This aloin-calcium salt could then be filtered and re-protonated in acid.  This 
method of aloin (2.1) precipitation seemed interesting and was thus investigated.  The A. 
marlothii leaf exudate was dissolved in hot water, followed by the addition of excess 
calcium chloride and ammonia.  Ammonia is a weak base (pKb = 4.7) and thus 
deprotonates the aloin phenolic groups (pKa = 10.0) in a reversible manner.  However, the 
reverse reaction is slightly more favourable with ammonium (pKa = 9.4) donating a proton 
to the deprotonated phenol (s) (pKb = 4.0).  The deprotonated phenol at either C-1/C-8 
combined with the neighbouring ketone functionality at position C-9, provide an ideal 
ligand for metal chelation (Scheme 2.1).  Thus, even though the equilibrium between the 
ammonia and aloin phenols favours the formation of ammonia (and not the ammonium 
salt), the small percentage of the phenols which are deprotonated react with the free Ca2+ in 
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solution and form the aloin calcium salt.  This insoluble aloin calcium salt precipitates out 















Aloin (2.1) can be regenerated by the addition of strong acidto this salt, which displaces 
the chelated calcium ion and re-protonates the phenolic hydroxy.  This aqueous solution 
can then be washed with ethyl acetate, which should extract the aloin (2.1) which can be 
isolated upon removal of the solvent.  It should also be noted that aloin (2.1) is roughly 2.3 
times more soluble in water than in ethyl acetate (due to the polar sugar moiety), thus 
multiple extractions are required for removal of the aloin (2.1).  The aloin (2.1) obtained 
from this procedure is of relatively high purity (∼ 90%). 
 
2.4 Synthesis of Aloin Derivatives 
 
The first aim of this project was to develop an effective procedure for the isolation of aloin 
(2.1) from the A. marlothii leaf exudate.  Since a method yielding large amounts of aloin 
(2.1) was found, the next step was to transform the anthro e into the desired synthetic 
anthraquinone derivatives.  The choice of derivatives to be made was based upon (i) 
known biologically active compounds (e.g. aloe-emodin ) and (ii) interesting biologically 
active functional groups (e.g. amines).  The planned synthetic pathway is shown below 













































































































2.4.1 Oxidation of Aloin (2.1) to Aloe-emodin (2.25) 
 
The oxidation of aloin (2.1) to aloe-emodin (2.25) is a naturally occurring event.  If aloin 
(2.1) is present in an oxidative medium, it is possible that the C-glucoside sugar is cleaved 
and the C-10 position to which it was attached is oxidized to a ketone.  This is the 
postulated origin of aloe-emodin (2.25) in Aloe plants, as an aloin (2.1) breakdown 
product20.  Thus it should be possible to obtain aloe-emodin (2.25) by simply leaving aloin 
(2.1) in an oxidative medium.  This is however an unreliable, time-consuming and 





















                                    (2.1)                                               (2.25) 
Scheme 2.3 
 
There are a number of published methods to oxidize aloin (2.1) to aloe-emodin (2.25), the 
most prominent being the FeCl3-mediated process (Scheme 2.4).  This reaction is low 
yielding (yields < 60% reported) and very inefficient as it requires a 5:1 ratio of FeCl3 to 
aloin (2.1)19. In our hands, this reaction afforded yields of 50% and was found to be 
extremely messy; thus other oxidation methods for the oxidation of aloin (2.1) to aloe-
emodin (2.25) were to be tested.  
 
















                          (2.1)                                                             (2.25) 
Scheme 2.4 
 
 In this investigation, a novel procedure to efficiently oxidize aloin (2.1) to aloe-emodin 
(2.25) was found.  A Co(II) catalyst (2.26) was found to do the necessary conversion in 
good yields, higher than those obtained in the FeCl3 process (Scheme 2.5).   
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                  (2.1)                                                                           (2.25) 
Scheme 2.5 
 
The Co(II) catalyst (2.26) was synthesized according to the published procedure21.    The 
catalyst requires a source of oxygen (H2O2 in this case).  A proposed mechanism of this 
oxidation is shown in Scheme 2.6.  The Co(II) catalyst (2.26), in aqueous solution, forms a 
mononuclear superoxo species (A).  Dioxygen then binds to the cobalt atom, and the Co(II) 
atom is oxidized to Co(III) (B)22.  The substrate, aloin (2.1), loses hydrogen at H-10 
resulting in the formation of an aloin radical (C).  The cobalt-bound dioxygen radical and 
aloin radical (C) then each donate an electron to form a bond between them.  Homolysis of 
the oxygen-oxygen bond and the C-glucosidic linkage generates aloe-emodin (2.25) and a 
glucose radical (D) that can be quenched by the cobalt species.  The formation of a ketone 
at C-10 of the anthraquinone is the driving force in this last step.  The extended 
conjugation allows for increased electron delocalization, thus promoting the stability of the 








































































































The Cu(II) derivative (2.27)23, which was reported to have the same oxidizing ability as the 
Co(II) complex (2.26), was also synthesized and tested on aloin (2.1) Scheme 2.7).   
 



















                                   (2.1) 
Scheme 2.7 
 
After 30 min, no aloin (2.1) or aloe-emodin (2.25) could be detected in the reaction 








2.4.2 Structural Elucidation of Aloe-emodin (2.25) 
 
The 1H NMR spectrum (Plate 5a) of aloe-emodin (2.25) had peaks characteristic of an 
aromatic compound with 10 protons.  Similarly to the parent compound aloin (Plate 1a), 
five proton signals were observed in the aromatic region of the 1H NMR spectrum, i.e., H-
2 (δH 7.29, s), H-7 (δH 7.37, d, J = 8.2 Hz), H-4 (δH 7.69, s), H-5 (δH 7.70, d, J = 7.4 Hz), 
H-6 (δH 7.78, t, J = 7.9).  The chemical shift of the methylene protons (δH 4.64, s) 
corresponds to that of a benzylic primary alcohol.  The phenolic hydroxy groups OH-8/ 
OH-1 (δH 11.80, br s, D2O exchangeable) can also be clearly observed downfield. 
 
The 13C NMR spectrum (Plate 5b) displayed a total of 15 carbons.  One CH2 carbon, five 
CH carbons and nine non-protonated carbons were identified.  In the 13C NMR spectrum, 
five aromatic signals (δC 117.1, 119.3, 120.7, 124.4, 137.2), four quaternary c bon peaks 
(δC 114.4, 115.8, 133.1, 133.3) and a signal depicting a benzylic methylene group (δC 
62.1).  Two signals characteristic of phenolic carbons (δC 161.3, 161.6) and two of  ketones 
(δC 190.9, 191.6) were also observed.  All these carbon NMR shifts, besides the new 
carbonyl carbon signal (δC 190.9), correlate with those of aloin (Plate 1b).  The difference 
between the NMR spectra of the two compounds is the absence of the sugar moiety in 
aloe-emodin (2.25). 
 
The DEPT 135 spectrum (Plate 5c) confirmed the presence of a single CH2 group as well 
as that of the five aromatic CH carbons.  An HSQC experiment (Plate 5e) showed 
correlations for all the carbon atoms with attached protons.  The HMBC experiment (Plate 
5f) showed correlations of C-8a with H-7 and H-5, of C-1a with 2-H and 4-H, and of C-3 
with 11-H2. 
 
2.4.3 Oxidation of Homonataloin (2.4) to Nataloe-emodin (2.28) 
 
Homonataloin (2.4) was oxidized to nataloe-emodin (2.28) (Scheme 2.8) using the same 
process used for the oxidation of aloin (2.1) to aloe-emodin (2.25) (Scheme 2.5).  Nataloe-




























                     (2.4)                                                                         (2.28) 
Scheme 2.8 
 
2.4.4 Structural Elucidation of Nataloe-emodin (2.28) 
 
The 1H NMR spectrum (Plate 6a) of nataloe-emodin (2.28) had peaks characteristic of an 
aromatic compound with 12 protons.  Similarly to the parent compound homonataloin 
(Plate 4a), four proton signals were observed in the aromatic region of the 1H NMR 
spectrum, i.e., H-2 (δH 7.15, s, J = 1.3 Hz), H-6 (δH 7.32, d, J = 8.2 Hz), H-4 (δH 7.47, d, J 
= 1.3 Hz), H-5 (δH 7.90, d, J = 8.3 Hz).  Signals for the 11-methyl group (δH 2.42) and the 
methoxy group (δH 3.84) are also observed.  The hydroxy groups 1-OH (δH 12.71) and 7-
OH (δH 10.84) correlate with those of the shifts of homonataloin. 
 
The 13C NMR spectrum (Plate 6b) displayed a total of 16 carbon signals.  One CH3 carbon, 
one OCH3 carbon, four CH carbons and ten non-protonated carbons were identified.  In the 
13C NMR spectrum, there were four aromatic signals (δC 119.8, 122.3, 123.9, 125.6) four 
signals corresponding to quaternary carbon atoms (δC 122.4, 126.2, 126.5, 132.9) and a 
signal indicating a benzylic methyl group (δC 21.9).  Three signals characteristic of 
phenolic carbons (δC 148.4, 148.6, 163.8) and two of carbonyl carbons (δC 188.6, 191.4) 
are also observed.  An HSQC experiment (Plate 6e) allowed for the correlation of all 
protonated carbon atoms with their attached protons. 
 
2.4.5 Oxidation of Aloe-emodin (2.25) to Rheinal (2. 9) 
 
Aloe-emodin (2.25) was oxidized to rheinal (2.29) using the highly efficient oxidizing 
agent o-idoxybenzoic acid (IBX) (2.30) (Scheme 2.9), which was synthesised based on the 
procedure provided in the literature24.  This safe, easily accessible reagent is highly 
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selective in the oxidation of alcohols to their corresponding aldehydes and ketones.  This is 
virtually a quantitative reaction which is achieved at room temperature in THF.  IBX (2.30) 
is insoluble in most solvents, with THF being an exception.  DMSO is often added to the 
reaction mixture in tiny amounts to improve the solubility of the IBX (2.30) and hence 















THF, RT, 12 h
95% yield
 
                          (2.25)                                                             (2.29)  
Scheme 2.9 
 
The oxidation of aloe-emodin (2.25) to rheinal (2.29) is proposed to occur by the 








































2.4.6 Structural Elucidation of Rheinal (2.29) 
 
The 1H NMR spectrum (Plate 8a) of rheinal (2.29) correlates with that of the parent 
molecule aloe-emodin (Plate 5a).  The proton spectrum of rheinal (2.29) differs from that 
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of aloe-emodin (2.25) by the absence of the H-11 methylene protons and the appearance of 
a strong aldehyde peak of H-11 (δH 10.12, s) downfield. 
 
Similarly to the 1H NMR spectrum, the 13C NMR spectrum (Plate 8b) of rheinal (2.29) also 
correlates with the 13C NMR spectrum of aloe-emodin (Plate 5b), except for a few 
differences.  The C-11 CH2 peak of aloe-emodin (2.25) is absent, and the aldehyde peak of 
rheinal (2.29) C-11 (δC 192.8) is observed.  The HSQC spectrum (Plate 8d) of rheinal 
clearly depicts the correlation of the aldehyde proton and the carbon to which it is attached.   
 
2.4.7 Oxidation of Rheinal (2.29) to Rhein (2.31) 
 
Rheinal (2.29) was converted to rhein (2.31) in a high yield by using sodium chlorite in a 
hydrogen phosphate buffer as the oxidation reagent.  (Scheme 2.11).  Similarly to the IBX 
oxidation, this was done at room temperature.  Sodium chlorite is a selective reagent for 
the oxidation of aldehydes to carboxylic acids, and has been utilized extensively in the 
carbohydrate field.  However, there is a limitation n this reaction, i.e.  the formation of the 
toxic chlorine dioxide gas.   This noxious gas may c use unwanted side reactions to occur.  














                         (2.29)                                                              (2.31) 
Scheme 2.11 
 
It was initially planned to obtain rhein (2.31) directly from aloe-emodin (2.25).  This 
transformation would mean that rhein (2.31) could be produced by a single step as opposed 
to two steps.  Heavy metal species such as chromic acid and potassium permanganate 
would very readily perform the necessary oxidations.  However, it is extremely difficult to 
remove all traces of these metals completely, which would be unacceptable for the 
biological testing of the synthesized products.  Several other benzylic oxidations were 
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tried, all of which proved either ineffective or resulted in a low yield, as described in 
Sections 2.4.9 to 2.4.11. 
 
 
2.4.8 Structural Elucidation of Rhein (2.31) 
 
The 1H NMR spectrum (Plate 9a) of rhein (2.31) differs from that of rheinal (2.29), by the 
absence of the aldehyde peak of H-11.  The 13C NMR spectrum (Plate 9b) of rhein (2.31) 
closely resembles that of rheinal (2.29), except for the upfield shift of C-11 (δC 181.4). 
 
2.4.9 Nickel Oxide Hydroxide Oxidation of Aloe-emodin (2.25) 
  
When nickel(II) chloride/nickel(II) acetate is exposed to commercial bleach (∼5% aqueous 
NaOCl), an insoluble nickel species is formed, named nickel oxide hydroxide.  This 
compound is a heterogeneous catalyst, used at a 2.5 mol % that is particularly useful in the 
oxidation of organic compounds.  Many different oxidat ons are possible: the oxidation of 
primary alcohols to carboxylic acids; secondary alcohols to ketones and aldehydes to 
carboxylic acids28.  This promising, cost-efficient catalyst was to be tested on the oxidation 













                   (2.25)                                                                        (2.31) 
Scheme 2.12 
 
Analysis of the reaction mixture showed no trace of ither starting material or the desired 
product.  The fate of this reaction was most probably the decomposition of the 
anthraquinone molecule.  The identical reaction was successfully tested on a model system, 
i.e., the oxidation of benzyl alcohol to benzoic acid which resulted in excellent yields 
(>95%).  This oxidation method was repeated several times on aloe-emodin (2.25), varying 
the experimental conditions.  This method was unsuccessful and thus was abandoned.    
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2.4.10 Oxidation of Aloe-emodin (2.25) with TEMPO (2.32)/NaOCl/NaClO2 
 
An interesting procedure to oxidize alcohols to their corresponding carboxylic acids is 
utilizing the combination of NaOCl, NaClO2 and TEMPO (2,2,6,6-tetramethylpiperidine-
1-oxyl) (2.32).  TEMPO (2.32) is a radical at room temperature.  The proposed mchanism 



























        
          (2.32)                                         
Scheme 2.13 
 
TEMPO (2.32) is catalytically converted to the N-oxoammonium cation (A) by NaOCl.  
This N-oxoammonium cation (A), being the active form of TEMPO (2.32), rapidly 
oxidizes the primary alcohol to its corresponding aldehyde, itself being converted to the 
hydroxylamine (B).  The aldehyde is then oxidized to its carboxylic a id derivative, 
generating a NaOCl molecule in the process which failit tes the initial oxidation29.  All 
three of these reagents are readily available at low cost, which is an added benefit. 
 
This oxidation method was tried on aloe-emodin (2.25) (Scheme 2.14), which proved 
unsuccessful.  Even after sufficiently increased reaction times and ratios of reagents, all 
that was present was the starting material.  It was postulated the TEMPO 
(2.32)/NaOCl/NaClO2 combination was too mild to oxidize the benzylic alohol next to an 














                               (2.25) 
Scheme 2.14 
 
2.4.11 Ruthenium Tetroxide Oxidation of Aloe-emodin (2.25) 
 
Ruthenium tetroxide (RuO4) is a powerful oxidation reagent used in organic synthesis.  It 
is a strong oxidant for many functional groups and is capable of cleaving double bonds.  
RuO4 is prepared by oxidation of either ruthenium(III) chloride or ruthenium dioxide with 
aqueous periodate or hypochlorite and then extracted into carbon tetrachloride.  Despite 
being an excellent oxidizing agent, there are many drawbacks to this reagent: It is 
expensive, corrosive, requires CCl4 as a co-solvent and is difficult to separate from the
reaction products30.  The oxidation of RuO4 on aloe-emodin (2.25) was carried out 









 CH3CN, CCl4, H2O, RT, 5 h
RuCl3.3H2O, NaIO4
 
                 (2.25)                                                                             (2.31) 
Scheme 2.15 
 
After 5 h of reaction time, the reaction was worked up and the products were isolated by 
chromatography.  The compounds isolated were rheinal (2.29) (10%), aloe-emodin (2.25) 
(80%) and rhein (2.31) (5%).  It was concluded that this reagent was not efficient enough 








2.4.12 Bromination of Aloe-emodin (2.25) to 11-Bromochrysophanol (2.33) 
 
The conversion of aloe-emodin (2.25) to 11-bromochrysophanol (2.33) was a necessary 
transformation to allow for a subsequent amination reaction, as bromine is a far better 
leaving group than oxygen.  This reaction has been published using HBr as the 
brominating medium32.  This is a high yielding process (89%) but milder methods were 





                                                         (2.33) 
 
2.4.13 Bromination of Aloe-emodin (2.25) Using CuBr/CBr4/Cu/Fe 
 
This interesting brominating technique centres around a Cu/Fe redox system.  Copper is 
the sacrificial anode, and iron is the cathode.  This reaction does not require the supply of 
electricity and occurs in a purely chemical mode.  The addition of 1,10-phenanthroline was 
reported to increase the efficiency of the reaction33.  The bromination of aloe-emodin 
(2.25) was tested using this system (Scheme 2.16), but all that was found was starting 





CH3CN, RT, 4 h
CBr4, CuBr, 1,10-Phenanthroline, Cu, Fe
No Reaction
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2.4.14 Bromination of Aloe-emodin (2.25) to 11-Bromochrysophanol (2.33) Using 
CBr 4/PPh3 
 
The second brominating system that was tested on aloe-emodin (2.25) was a combination 















Initially a ratio of CBr4/PPh3 (1:1) to aloe-emodin (2.25) in toluene was tested and resulted 
in low yields (<50%).  Thereafter an increased ratio of CBr4/PPh3 (4:4) to aloe-emodin 
(2.25) in THF was tested and resulted in greatly improved yields (>90%).  This method 
was based on a benzylic bromination reported in the literature34. 
 
2.4.15 Structural Elucidation of 11-Bromochrysophanol (2.33) 
 
The 1H NMR spectrum (Plate 10a) of 11-bromochrysophanol (2.33) correlates closely with 
that of the parent molecule aloe-emodin (2.25).  The proton spectrum of 11-
bromochrysophanol (2.33) differs from that of aloe-emodin (2.25) in the downfield shift of 
the benzylic proton signal from δH 4.64, in aloe-emodin (2.25), to δH 4.81, in 11-
bromochrysophanol (2.33).  This shift of the methylene proton signal reflects the chemical 
transformation of the hydroxy group to a bromide.    
 
The 13C NMR spectrum (Plate 10b) of 11-bromochrysophanol (2.33) is similar to that of 
aloe-emodin (2.25).  The carbon signal at δC 25.1 is due to C-11 attached to a bromine 
atom.  The signal at δC 62.0 corresponds to that of a benzylic CH2 attached to a hydroxy 
group (C-11), exactly like that of aloe-emodin (2.25).  The solvent that was used for the 
NMR spectroscopy was deuterated DMSO, which has trace amounts of water.  DMSO, 
being an extremely hygroscopic compound, absorbs water from the atmosphere once it is 
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exposed to it.  It was postulated that the 11-bromochrysophanol (2.33) was transformed 
back to aloe-emodin (2.25) whilst undergoing the 13C NMR experiment by reacting with 
the water present in the deuterated DMSO.  The absence of signals for aloe-emodin (2.25) 
in the proton spectrum confirmed this. 
 
2.4.16 Substitution Reaction of 11-Bromochrysophanol (2.33) 
 
The conversion of 11-bromochrysophanol (2.33) to amine derivatives has been reported in 
the literature.  Fifteen aloe-emodin amine derivatives have been synthesized by Koyama et 
al. in an attempt to produce novel potential anticancer agents15.  More recently, Cui et al. 
completed a similar study on these aloe emodin amine derivatives35.  The published 
protocol for producing these amines involves stirring 11-bromochrysophanol (2.33) in dry 
DMF in the presence of an excess of the desired amine in excess for three days.  Low 
yields (<60%) were reported for this slow reaction.  Three amine derivatives of aloe-
emodin (2.25), i.e.  11-(pyrrolidin-1-yl)chrysophanol (2.34), 11-(piperidin-1-
yl)chrysophanol (2.35) and 11-(morpholin-1-yl)chrysophanol (2.36) were required for this 
research project.  Of these three aloe-emodin (2.25) derivatives, only the 11-(morpholin-1-
yl)chrysophanol (2.36) is novel.  It was postulated that the amination reaction would occur 
at a much faster rate if the amine was deprotonated.  A strong base such as BuLi was 






         (2.34)                                        (2.35)                                         (2.36) 
 
2.4.17 Amination Reaction of 11-Bromochrysophanol (2.33)  
 
BuLi (2.37) was carefully added to freshly distilled morpholine (2.38) in dry THF.  The 
deprotonated morpholine (2.39) was added to 11-bromochrysophanol (2.33) and stirred for 
12 h at RT.  11-(Morpholin-1-yl)chrysophanol (2.36) was formed (Scheme 2.18).   
 




















                                                                                                 
                                                                                                    (2.36)                                               
Scheme 2.18 
 
The work up of the reaction (Scheme 2.19) starts off with the addition of hydrochloric acid 
to reprotonate the two phenolic groups at positions C-1 and C-8.  These phenolic protons 
(pKa = 10.0) were removed by the excess deprotonated amine anions.  The reaction 
mixture was then neutralised with NaHCO3.  This was done to neutralise the ammonium 
cation formed.  The reaction mixture was chromatographed to afford the 11-(morpholin-1-



















                                
                                                                                           (2.36) 
Scheme 2.19 
 
The synthesis of 11-(morpholin-1-yl)chrysophanol (2.36), the 11-(piperidin-1-
yl)chrysophanol (2.35) and 11-(pyrrolidin-1-yl)chrysophanol (2.34) derivatives was 
























2.4.18 Structural Elucidation of 11-(Pyrrolidin-1-yl)chrysophanol (2.34) 
 
The proton spectrum of 11-(pyrrolidin-1-yl)chrysophanol (2.34) differs from that of aloe-
emodin (2.25).  Firstly, there is a considerable upfield shift o  the signal for the 11-
methylene protons from δH 4.64, in aloe-emodin (2.25), to δH 3.75, in 11-(pyrrolidin-1-
yl)chrysophanol (2.34).  This change in chemical shift reflects the substitution of the 
bromine atom by a nitrogen atom, i.e. the pyrrolidine group.  The pyrrolidine-nitrogen 
atom, which has three covalent bonds, is less electronegative then the bromine atom and 
thus the methylene protons experience an upfield shift.  The pyrrolidine CH2 atoms H-2’ 
(δH 1.74, m) and H-1’ (δH 2.42, m) are also present in the spectrum, integrating to eight 
protons in total.   
 
The 13C NMR (Plate 11b) of 11-(pyrrolidin-1-yl)chrysophanol (2.34) is  similar to that of 
aloe-emodin (2.25).  The carbon signal at δC 59.1 is that of C-11 attached to the nitrogen-
atom of the pyrrolidine.  The shifts of the pyrrolidine carbon atoms are also observed, C-2’ 
(δC 25.7) and C-1’ (δC 54.0).  The HMBC spectrum (Plate 11f) shows connections of C-11 
with H-1’and vice versa. 
 
2.4.19 Structural Elucidation of 1-(Piperidin-1-yl)chrysophanol (2.35) 
 
The 1H NMR spectrum (Plate 12a) of 1-(piperidin-1-yl)chrysophanol (2.35) resembles that 
of 11-(pyrrolidin-1-yl)chrysophanol (2.35), being a structurally similar compound.  There 
are the amine, i.e. piperidine in this case, protons H-3’ (δH 1.43, m), H-2’ (δH 1.58, m) and 
H-1’ (δH 2.41, m) present.  There is also an upfield shift of the H-11 methylene protons to 
δH 3.55. 
 
The 13C NMR spectrum (Plate 12b) of 11-(piperidin-1-yl)chrysophanol (2.35) is similar to 
that of aloe-emodin (2.25).  The carbon shift at 63.1 is that of C-11 attached to the 
nitrogen-atom of the piperidine.  The signals for the piperidine carbon atoms are also 
observed, C-3’ (δC 25.9), C-2’ (δH 25.9) and C-1’ (δH 54.7).  The HMBC spectrum (Plate 





2.4.20 Structural Elucidation of 11-(Morpholin-1-yl)chrysophanol (2.36) 
 
The 1H NMR spectrum (Plate 13a) of 11-(morpholin-1-yl)chrysophanol (2.36) correlates 
with that of aloe-emodin (2.25).  There is an upfield shift of the H-11 methylene protons 
from δH 4.64, in aloe-emodin (2.35), to δH 3.60, in 11-(morpholin-1-yl)chrysophanol 
(2.36).  The morpholine proton atoms H-1’ (δH 2.40, m) and H-2’ (δH 3.61, m), are also 
observed. 
 
The 13C NMR spectrum (Plate 13b) of 11-(morpholin-1-yl)chrysophanol (2.36) is highly 
similar to that of aloe-emodin (2.25).  The carbon shift at δC 62.0 is that of C-11 attached to 
the nitrogen-atom of the morpholine.  The shifts of the morpholine carbon atoms are also 
observed, C-1’ (δC 53.6) and C-2’ (δH 66.7).  The HMBC spectrum (Plate 13f) shows 




A method to isolate aloin (2.1) from the A. marlothii leaf exudate was developed using a 
selective calcium precipitation.  Aloin (2.1) was successfully transformed into several 
derivatives, which were all purified using column chromatography.  The structures of these 




All the required chemicals or reagents were obtained from FLUKA, SIGMA-ALDRICH or 
MERCK and were used without further purification.  All reactions requiring anhydrous 
solvents were performed under a nitrogen atmosphere. 
 
Nuclear magnetic resonance spectroscopy (NMR) of the isolated compounds was 
performed on either a Bruker 400 MHz or 500 MHz spectrophotometer.  All NMR spectra 
were recorded at 25 oC and the chemical shifts were recorded in ppm referenced to the 
tetramethylsilane as zero.  Coupling constants are c lculated as observed in the 1H NMR 
spectra.  Deuterated methanol (MeOH-d4) or DMSO-d6 were used as solvents for polar 
compounds and deuterated chloroform (CDCl3) was used for non-polar compounds.  Mass 
spectra were obtained with a Waters-LCT-Premier mass-spectrometer.   
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Thin-layer chromatography (TLC) of the compounds was performed with glass backed 
silica plates (Merck 0.20 mm).  The TLC-plates were viewed under UV light (λ 254 and 
366 nm) and subjected to iodine or anisaldehyde spray reagent (6 g anisaldehyde in 250 ml 
ethanol containing 2.5 ml concentrated sulfuric acid).  Once the plates were sprayed they 
were heated in an oven to allow for the colour development. 
 
Normal and flash chromatography were performed with silica gel 60 (Merck 0.040-
0.063 m) and on columns with diameters of 2 cm, 4 cm or 6 cm.  The extracts or mixed 
fractions were absorbed onto silica and were then packed onto columns.  Both isocratic and 
gradient eluent systems were employed. 
 



















































A. marlothii leaf exudate was sourced from Ladysmith and was obtained as follows: 
Leaves were harvested with sickles and carefully stacked in a circle with the cut surfaces 
facing inwards.  A plastic sheet was placed in the middle to collect the leaf exudates.   
Freeze-dried A. marlothii leaf exudate (5.0 g) was chromatographed on silica gel, eluting 
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with an EtOAc-MeOH-CH3CN [75:10:2 (v/v)] running phase.  Column fractions were 
monitored by silica gel TLC (solvent, EtOAc-MeOH-CH3CN, 75:10:2 v/v), and four major 
compounds were observed.  The fractions containing each compound were collected, 
combined and the solvent was removed using a rotary evaporator followed by high 
vacuum.  The four compounds were then subjected to NMR analysis.  The structure of the 
compounds (based on the column elution order) were elucidated to be homonataloin (2.4) 
(400 mg, Rf = 0.75, 8%), aloeresin A (2.2) (1600 mg, Rf = 0.65, 32%), aloin (2.1) (1100 
mg, Rf = 0.58, 22%) and aloesin (2.3) (1800 mg, Rf = 0.38, 36%) respectively.   
 
Homonataloin (2.4): Yellow amorphous solid comprising an unresolved mixture of 
homonataloin A and homonataloin B; UV (MeOH) λMax (log ε): 213 (8.62), 295 (4.79), 
352 (1.51) nm; IR (KBr) νmax:. 3385, 2923, 1702, 1633, 1607, 1483, 1433, 1359, 1270, 
1216, 1169 cm-1. 
NMR analysis revealed signals for both isomers. 
 Homonataloin A. 1H NMR (DMSO-d6, 400 MHz): δH 2.29 (3H, s, H-11), 2.75-2.81 (2H, 
m, H-2’, H-4’), 3.11-3.16 (3H, m, H-1’, H-6’b, H-5’), 3.31 (1H, d, H-6’a), 3.74 (3H, s, H-
12), 4.38 (2H, s, H-10), 6.62 (1H, s, H-2), 6.76 (1H, s, H-4), 7.08 (1H, s, H-5), 7.13 (1H, s, 
H-6), 9.55 (1H, br s, D2O exchangeable, OH-7), 12.10 (1H, br s, D2O exchangeable, OH-
1)(A)13C NMR (DMSO-d6, 400 MHz): δC 21.9 (C-11), 49.1 (C-10), 61.4 (C-12), 62.1 (C-
6’), 70.8 (C-2’), 70.9 (C-4’), 78.4 (C-3’), 80.4 (C-5’), 84.2 (C-1’), 115.6 (C-2), 118.0 (C-
8a), 119.2 (C-4), 121.9 (C-5), 123.8 (C-6), 127.4 (C-9a), 136.2 (C-4a), 140.8 (C-5a), 145.2 
(C-7), 147.5 (C-8), 150.1 (C-3), 160.4 (C-1), 190.1 (C-9). 
Homonataloin B. 1H NMR (DMSO-d6, 400 MHz): δH 2.29 (3H, s, H-11), 2.75-2.81 (2H, 
m, H-2’, H-4’), 3.11-3.16 (3H, m, H-1’, H-6’b, H-5’), 3.31 (1H, d, H-6’a), 3.74 (3H, s, H-
12), 4.38 (2H, s, H-10), 6.64 (1H, s, H-2), 6.82 (1H, s, H-4), 7.06 (1H, s, H-5), 7.13 (1H, s, 
H-6), 9.51 (1H, br s, D2O exchangeable, OH-7), 12.10 (1H, br s, D2O exchangeable, OH-
1)(B)13C NMR (DMSO-d6, 400 MHz): δC 21.9 (C-11), 49.1 (C-10), 61.4 (C-12), 62.1 (C-
6’), 70.8 (C-2’), 70.4 (C-4’), 78.1 (C-3’), 80.1 (C-5’), 84.2 (C-1’), 115.9 (C-2), 117.7 (C-
8a), 120.7 (C-5), 120.9 (C-4), 123.8  (C-6), 127.7 (C-9a), 132.0 (C-4a),140.8 (C-5a), 
145.22 (C-7), 147.8 (C-8), 150.1 (C-3), 160.4 (C-1), 90.1 (C-9). HR-TOF-MS: m/z 




Aloeresin A (2.2): Yellow amorphous solid; 1H NMR (400 MHz, MeOH-d4): δH 2.34                 
(3H, s, H-11), 2.63 (3H, s, H-12), 3.44-3.57 (2H, m, H-4’,H-5’), 3.65-3.75 (3H, m, H-3’, 
H-2’, H-6’b), 3.80-3.95 (3H, m, H-6’a, H-9), 4.53 (1H, d, H-1’), 5.14 (1H, d, H-2’), 6.06 
(1H, d, J = 16.0 Hz, H-2’’), 6.20 (1H, s, H-3), 6.58 (2H, t, J = 8.5 Hz, H-6’’, H-8’’), 7.32 
(2H, d, J = 8.0 Hz, H-5’’, H-9’’), 7.40 (1H, d, J = 16.0 Hz, H-3’’); 
13C NMR (MeOH-d4, 
400 MHz): δC 23.2 (C-12), 26.4 (C-11), 48.0 (C-9), 61.9 (C-6’), 72.1 (C-4’), 72.2 (C-1’), 
73.8 (C-2’), 77.8 (C-3’), 82.7 (C-5’), 108.7 (C-8), 112.1 (C-3), 113.4 (C-2’’), 114.9 (4a), 
115.4 (C-6’’, C-8’’), 115.8 (C-6), 127.1 (C-4’’), 131.1 (C-5’’, C-9’’), 159.8 (C-8a), 161.1 
(C-2, C-7), 168.1 (C-1’’), 182.0 (C-4), 204.7 (C-10). HR-TOF-MS: m/z 539.1551 [M-H]- 
(calculated for C28H27O11, 539.1553).  
 
Aloin (2.1): Yellow amorphous solid; UV (MeOH) λMax (log ε): 261 (5.79), 269 (5.86), 
297 (5.93), 359 (6.02) nm; IR (KBr) νmax:. 3328, 1634, 1601, 1490, 1428, 1335, 1287, 1164 
cm-1; 1H NMR (MeOH-d4, 400 MHz): δH 2.84 (1H, m, H-5’), 2.85 (1H, t, J = 9.2 Hz, H-
4’), 2.96 (1H, t, J = 9.2 Hz, H-2’), 3.28 (1H, t, J = 9.2 Hz, H-3’), 3.33 (1H, m, H-6’b), 3.35 
(1H, t, J = 9.2 Hz, H-1’), 3.44 (1H, m, H-6’a), 4.56 (1H, d, Ja,b = 14.6 Hz, H-11), 4.69 (2H, 
d, J = 2.4 Hz, H-10), 6.68 (1H, d, J = 8.6 Hz, H-7), 6.78 (1H, d, J = 1.5 Hz, H-2), 6.94 (1H, 
d, J = 1.5 Hz, H-5), 7.04 (1H, d, J = 8.6 Hz, H-4), 7.47 (1H, t J = 7.9, H-6), 11.35 (1H, br 
s, D2O exchangeable, OH-8), 11.68 (1H, br s, D2O exchangeable, OH-1); 
13C NMR 
(MeOH-d4, 400 MHz): δC 45.9 (C-10), 63.3 (C-6’), 64.5 (C-11), 71.8 (C-2’), 72.0 (C-4’), 
80.0 (C-3’), 81.6 (C-5’), 86.6 (C-1’), 114.4 (C-2), 116.8 (C-7), 117.7 (C-9a), 118.7 (C-8a), 
119.1 (C-4), 120.0 (C-5), 137.0 (C-6), 143.2 (C-4a), 146.6 (C-5a), 151.5 (C-3), 162.9 (C-
1), 163.4 (C-8), 195.5 (C-9); HR-TOF-MS: m/z 417.1185 [M-H]- (calculated for C21H21O9, 
417.1186) 
 
Aloesin (2.3): White powder; 1H NMR (MeOH-d4, 400 MHz): δH 2.29 (3H, s, H-11), 2.70              
(3H, s, H-12), 3.45-3.56 (3H, m, H-3’, H-4’, H-5’), 3.75 (1H, m, H-6’b), 3.83-3.90 (2H, m, 
H-6’a, H-9), 4.02 (1H, m, H-2’), 4.98 (1H, d, H-1’) 6.14 (1H, s, H-3), 6.70 (1H, s, H-6); 
13C NMR (MeOH-d4, 400 MHz): δC 23.2 (C-12), 29.9 (C-11), 49.0 (C-9), 62.9 (C-6’), 70.4 
(C-4’), 71.6 (C-2’), 74.2 (C-1’), 79.9 (C-3’), 82.5 (C-5’), 111.3 (C-4a), 113.4 (C-6, C-3), 
116.2 (C-8), 116.8 (C-6), 143.3 (C-5), 158.4 (C-8a), 161.7 (C-7), 162.6 (C-2), 182.0 (C-1), 




2.62 Isolation of Aloin (2.1) via formation of Calcium salt 
 
A. marlothii leaf exudate (50.0 g) was dissolved in hot water (300 ml), in a large beaker, 
and stirred thoroughly to form a dark yellow syrupy mixture.  Anhydrous CaCl2 (50.0 g, 
0.450 mmol) and NH3 (25%) (~15 ml) were then added to the solution.  The mixture was 
stirred vigorously for 10 min and allowed to settle.  Within a few minutes the mixture 
thickened and an orange-yellow precipitate formed.  The precipitate was vacuum filtered 
using a large Büchner funnel and flask, and the orange cake that remained was washed 
with water until it became a bright yellow colour.  The supernatant was discarded and the 
yellow precipitate was transferred into a large beaker.  The precipitate was slowly treated 
with HCl (5 M, 100 ml).  The mixture was stirred slowly and water (200 ml) was added.  
The orange-red solution was transferred into a large separatory funnel and this aqueous 
layer was washed several times with ethyl acetate (10 x 300 ml).  The organic layers were 
combined, dried over anhydrous MgSO4 and filtered with a Büchner funnel and flask.  The 
solvent was then removed using a rotary evaporator to yield a lemon-yellow powder (10.0 
g).  A portion of this product (0.2 g) was subjected o a silica chromatography column 
using an EtOAc-MeOH-CH3CN [75:10:2 (v/v)] solvent system to afford clean aloin (2.1) 
(0.188 g, 0.45 mmol, 94%).    
 











Aloin (2.1) (100 mg, 0.24 mmol ) and anhydrous FeCl3 (500 mg, 3.1 mmol) were dissolved 
in hot water (10 ml) in a round bottom flask equipped with a magnetic stirrer bar and 
reflux condenser.  The dark solution was then reflux d for 6 h at 120 oC.  The mixture was 
cooled to RT and cold water (10 ml) was added.  Thedark orange mixture was then 
washed with dichloromethane (3 x 20 ml).  The organic layers were combined, dried over 
anhydrous MgSO4, filtered with a Bϋchner funnel and flask and the solvent was then 
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removed using a rotary evaporator to afford aloe-emodin (2.25) as an orange-brown sweet 
smelling solid (32.4 mg, 0.12 mmol, 50%). 
 
Aloe-emodin (2.25): Orange solid; UV (MeOH) λMax (log ε) : 255 (2.74), 276 (2.55), 286 
(2.55), 429 (2.45) nm; IR (KBr) νmax:. 2924, 1674, 1627, 1454, 1388, 1284, 1213, 1170 cm
-
1; 1H NMR (400 MHz, DMSO-d6): δH 4.64 (2H, s, H-11), 5.59 (1H, br s, D2O 
exchangeable, OH-11), 7.29 (1H, s, H-2), 7.37 (1H, d, J = 8.2 Hz, H-7), 7.69 (1H, s H-4), 
7.70 (1H, d, J = 7.4 Hz, H-5), 7.78 (1H, t J = 7.9 Hz, H-6), 11.80 (2H, br s, D2O 
exchangeable, OH-1, OH-8).  13C NMR (400 MHz, DMSO-d6): δC 62.1 (C-11), 114.4 (C-
9a), 115.8 (C-8a), 117.1 (C-4), 119.3 (C-5), 120.7 (C-2), 124.4 (C-7), 133.1 (C-4a), 133.3 
(C-5a), 137.2 (C-6), 153.7 (C-3), 161.3 (C-1), 161.6 (C-8), 190.9 (C-10), 191.6 (C-9). HR-
TOF-MS: m/z 269.0437 [M-H]- (calculated for C15H9O5, 269.0450).  
 













Salicylaldehyde (1.22 g, 10 mmol) and ethylene diamine (300 mg, 5 mmol) were reacted 
together in MeOH (50 ml) and stirred rapidly in a round bottom flask, which resulted in the 
rapid formation of a lemon yellow precipitate (salen[2,2'-
ethylenebis(nitrilomethylidene)diphenol]-H2, 1.80 g, 67%) NaBH4 (400 mg, 10 mmol) 
was slowly added to the mixture, and stirred for 2 h at RT.  The solvent was then removed 
using a rotary evaporator to yield a colourless powder (salen-H4, 1.40 g, 62%), which was 
washed with distilled water (20 ml) and air dried.  IR (KBr) νmax:  3288, 2909, 2868, 2827, 
1608, 1565, 1398, 1260, 999 cm-1; 1H NMR (400 MHz, CDCl3): δH 2.85 (4H, s, H-2), 3.9 
(4H, dd, H-1), 6.7-7.2 (8H, m, benzene).  Salen-H4 (150 mg, 0.55 mmol) and Co(II) acetate 
(200 mg, 1.10 mmol) were dissolved in MeOH (10 ml) and stirred for 2.5 h under N2 at 50 
oC.  The removal of the solvent on a rotary evaporator afforded a powder which 
chromatographed on a silica chromatography column usi g a mixture of EtOAc-MeOH 
(15:5) to afford the Co(II) catalyst (2.26) as a green powder (110 mg, 0.33 mmol, 61%): 
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UV (CH3CN): λmax 262 (2.86), 384 (2.08) nm.  HR-TOF-MS: m/z 330.0700 [M+H]
+ 
(calculated for C16H18O2N2Co, 329.0700). 
 
2.6.5 Co(II) Catalysed (2.26) Oxidation of Aloin (2.1) to Aloe-emodin (2.25) 
 
Aloin (2.1) (200 mg, 0.487 mmol), Co(II) catalyst (2.26) (25 mg, 0.076 mmol) and 30% 
H2O2 (3 ml, 26 mmol) were dissolved in CH3CN (5 ml) in a round bottom flask equipped 
with magnetic stirrer and reflux condenser.  The mixture was refluxed for 8 h at 80 oC and 
then allowed to cool to RT.  The solution was then extracted with diethyl ether (3 x 80 ml), 
dried over anhydrous MgSO4, filtered and the solvent was removed via a rotary evaporator.  
The orange material was then subjected to column chromatography, using diethyl ether as 
the eluent.  The first fast running orange band wascollected, and the solvent was removed 
to afford aloe-emodin (2.25) as a dull orange solid (92 mg, 0.34 mmol, 70%).   
 













Salicylaldehyde (1.22 g, 10 mmol) and ethylene diamine (300 mg, 5 mmol) were stirred 
together in MeOH (50 ml), which resulted in the rapid formation of a lemon yellow 
precipitate (salen-H2, 1.80 g, 67%).  NaBH4 (400 mg, 10 mmol) was slowly added to the 
mixture, and stirred for 2 h at RT.  The solvent was then removed using a rotary evaporator 
to yield a colourless powder (salen-H4, 1.40 g, 62%), which was washed with distilled 
water (20 ml) and air dried.  IR (KBr) νmax: 3288, 2909, 2868, 2827, 1608, 1565, 1398, 
1260 cm-1; 1H NMR (400 MHz, CDCl3): δH 2.85 (4H, s, H-2), 3.9 (4H, dd, H-1), 6.7-7.2 
(8H, m, benzene).  Salen-H4 (150 mg, 0.55 mmol) and Cu(II) acetate (200 mg, 1 mmol) 
were dissolved in MeOH (10 ml) and stirred for 2.5 h under N2 at 50 
oC.  The removal of 
the solvent on a rotary evaporator afforded a powder which was chromatographed on a 
silica chromatography column using a EtOAc-MeOH (15:5) eluent to afford the Cu(II) 
catalyst (2.27) as a green powder (160 mg, 0.48 mmol, 87%): UV (CH3CN) λmax (log ε) :  
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385 (2.39), 585 (1.88) nm.  HR-TOF-MS: m/z 334.0757 [M+H]+ (calculated for 
C16H18O2N2Cu, 334.0743). 
 
2.6.7 Cu(II) Catalysed (2.27) Oxidation of Aloin (2.1)  
 
Aloin (2.1) (200 mg, 0.487 mmol), Cu(II) catalyst (2.27) (25 mg, 0.075 mmol) and 30% 
H2O2 (3 ml, 26 mmol) were dissolved in CH3CN (5 ml) in a round bottom flask equipped 
with magnetic stirrer and reflux condenser.  The mixture was refluxed for 8 h at 80 oC and 
then allowed to cool to RT.  TLC analysis of the reaction showed no trace of starting 
material [aloin (2.1)] or of the expected product [aloe-emodin(2.25)], only the presence of 
the Cu(II) catalyst and its breakdown products.   
 












Homonataloin (2.4) (1000 mg, 2.31 mmol), Co(II) catalyst (2.27) (100 mg, 0.30 mmol) and 
30% H2O2 (15 ml, 130 mmol) were dissolved in CH3CN (50 ml) in a round bottom flask 
equipped with magnetic stirrer and reflux condenser.  The mixture was refluxed for 8 h at 
80 oC and then allowed to cool to RT.  The solution was then extracted with diethyl ether 
(3 x 80 ml), dried over anhydrous MgSO4, filtered and the solvent was removed via a 
rotary evaporator.  The orange material was then chromatographed on a silica column, 
using diethyl ether as the eluent.  The first fast running orange band was collected, and the 
solvent was removed to afford nataloe-emodin (2.28) as a dull orange solid (460 mg, 1.06 
mmol, 70%).   
 
Nataloe-emodin (2.28): Orange solid; UV (MeOH)  λMax (log ε): 274 (3.68), 295 (2.32), 
329 (5.67), 401 (1.22) nm; IR (KBr) νmax: 2924, 2854, 1637, 1606, 1566, 1481, 1427, 
1362, 1295, 1205, 1157 cm-1; 1H NMR (DMSO-d6, 400 MHz): δH 2.42 (3H, s, H-11), 3.84 
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(3H, s, H-12), 7.15 (1H, d, J = 1.3 Hz, H-2), 7.32 (1H, d, J = 8.2 Hz, H-6), 7.47 (1H, d, J = 
1.3 Hz, H-4), 7.90 (1H, d, J = 8.3 Hz, H-5), 10.84 (1H, br s, D2O exchangeable, OH-7) 
12.71 (1H, br s, D2O exchangeable, OH-1).
13C NMR (DMSO-d6, 400 MHz): δC 21.9 (C-
11), 60.9 (C-12), 115.3 (C-3), 119.8 (C-4), 122.3 (C-6), 122.4 (C-4a), 123.9 (C-2), 125.6 
(C-5), 126.2 (C-8a), 126.5 (C-9a), 132.9 (C-4a), 148.4 (C-8), 148.6 (C-7), 158.4 (C-5a), 
163.8 (C-1), 188.6 (C-10), 191.4 (C-9).  HR-TOF-MS: m/z 283.0602 [M-H]- (calculated 
for C16H11O5, 283.0606). 
 

















KBrO3 (4.00 g, 24 mmol) was dissolved in H2SO4 (2 M, 38 ml) in a two-necked round 
bottom flask equipped with a magnetic stirrer bar, reflux condenser and thermometer.  The 
clear solution was heated to 60 oC and o-iodobenzoic acid (4.00 g, 16 mmol) was added 
over 40 min in small (0.5 g) portions.  The mixture b came a bright orange colour as Br2
gas was evolved and a white precipitate emerged.  After the addition was complete, the 
temperature was maintained at 65 oC for 3 h.  The solution was then cooled in an ice bath 
and the solid material was collected by vacuum filtration with a Bϋchner funnel and flask.  
The white precipitate was washed with cold H2O (500 ml), cold EtOH (500 ml) followed 
by cold water (500 ml).  The IBX (2.30) was air dried and weighed (2.00 g, 7.14 mmol, 
44%). 
 
IBX (2.30): White powder; 1H NMR (400 MHz, DMSO-d6): δH 7.83 (1H, t, J = 8.3 Hz, H-
3), 7.98 (1H, t, J = 8.3 Hz, H-2), 8.02 (1H, d, J = 12.8 Hz, H-4), 8.14 (1H, d, J = 12.8 Hz, 
H-1); 13C NMR (400 MHz, DMSO-d6): δC 125.5 (C-1), 130.6 (C-4), 131.6 (C-4a), 133.5 
(C-3), 134.9 (C-2), 147.0 (C-1a), 168.0 (C-5); HR-TOF-MS: m/z 278.9154 [M-H]- 
(calculated for C7H4O6I, 278.9154).     
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Aloe-emodin (2.25) (100 mg, 0.37 mmol) was dissolved in dry THF (8 ml).  IBX (2.30) 
(155 mg, 0.55 mmol) and DMSO (2 ml) were added to the mixture which was stirred for 8 
h at RT.  The solution was transferred to a separatory funnel, where H2O (20 ml) was 
added and the resulting orange mixture was washed with diethyl ether (4 x 50 ml).  The 
organic layers were combined, dried over anhydrous MgSO4 and filtered with a Buchner 
funnel and flask.  The solvent was then removed using a rotary evaporator to yield an 
orange-yellow solid which was purified by silica column chromatography using diethyl 
ether as the eluent.  Rheinal (2.29) was obtained in excellent yields (94.2 mg, 0.35 mmol, 
95%) 
 
Rheinal (2.29): Orange amorphous solid; UV (MeOH)  λMax (log ε) : 253 (2.69), 274 
(2.37), 285 (2.36), 429 (2.43) nm; IR νmax (neat) :.  2922, 2640, 1670, 1622, 1602, 1427, 
1400, 1287, 1264, 1157, 1108 cm-1; 1H NMR (500 MHz, DMSO-d6): δH 7.42 (1H, d, J = 
8.3 Hz, H-7), 7.76 (1H, d, J = 7.5 Hz, H-5), 7.82 (1H, s, H-2), 7.84 (1H, t, J = 8.1 Hz, H-
6), 8.13 (1H, d, J = 1.2 Hz, H-4), 10.12 (1H, s, H-11) 11.83 (2H, br s, D2O exchangeable, 
OH-1, OH-8); 13C NMR (500 MHz, DMSO-d6): δC 116.8 (C-8a), 118.5 (C-4), 119.9 (C-5), 
120.1 (C-9a), 124.8 (C-2), 125.2 (C-7), 133.8 (C-4a), 134.8 (C-5a), 138.1 (C-6), 141.9 (C-
3), 161.4 (C-1), 162.0 (C-8), 191.9 (C-10), 192.8 (C-9), 192.8 (C-11); HR-TOF-MS: m/z 
267.0289 [M-H]- (calculated for C15H7O5, 267.0293).   
 
2.6.11 Oxidation of Aloe-emodin (2.25) with Nickel Oxide Hydroxide 
 
Aloe-emodin (2.25) (150 mg, 0.56 mmol), NiCl2.6H2O (12.5 mg, 0.053 mmol), H2O (0.1 
ml) and DCM (0.2 ml) were added together and cooled in an ice bath.  Cold NaOCl (3.5%, 
10 ml) was added and, instantaneously, a black slurry formed.  The mixture was stirred for 
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8 h (5 ml NaOCl was added after 3  h) at 0 oC and for 11 h at RT.  The reaction mixture 
was acidified using HCl (5 M) and extracted with EtOAc (3 x 20 ml).  The organic layers 
were combined, dried over anhydrous MgSO4 and filtered with a Buchner funnel and flask.  
The solvent was then removed using a rotary evaporator.  No trace of starting material 
[aloe-emodin (2.25)] or of desired product [rhein (2.31)] were found. 
 
2.6.12 Oxidation of Aloe-emodin (2.25) with TEMPO (2.32)/NaOCl/NaClO2 
 
Aloe-emodin (2.25) (50 mg, 0.185 mmol), TEMPO (2.32) (2.2 mg, 0.011 mmol) and 
NaH2PO4 buffer (0.75 ml, pH = 6.7) were added together in a round bottom flask and the 
solution was heated to 35 oC.  Next, NaOCl (46 mg, 0.4 mmol in 0.2 ml H2O) and NaOCl 
(3.5%, 1 ml) were added to the stirred reaction over 2 h.  The deep-purple reaction mixture 
was then stirred for 12 h at 35 oC.  The solution was then acidified with HCl (3 M).  TLC 
analysis showed only starting material.   
 
2.6.13 RuO4 Oxidation of Aloe-emodin (2.25) 
 
Aloe-emodin (2.25) (50 mg, 0.19 mmol), NaIO4 (214 mg, 1 mmol, 5 mol%), CH3CN (0.8 
ml), CCl4 (0.8 ml) and H2O (1.2 ml) were added together in a round bottom flask equipped 
with magnetic stirrer.  The mixture was stirred for 5 min at RT and RuCl3.3H2O (13.1 mg, 
0.050 mmol, 0.25 mol%) was added.  The reaction was stirred vigorously for 5 h at RT.  
The reaction material was chromatographed on silica gel, eluting with a diethyl 
ether/petroleum ether (15:10 v/v) running phase.  Thee compounds were isolated, aloe-
emodin (2.25) (43 mg, 0.16 mmol, 84%), rheinal (2.29) (5 mg, 0.019 mmol, 10%) and 
rhein (2.31) (3 mg, 0.0095 mmol, 5%).   
 












Rheinal (2.29) (150 mg, 0.56 mmol) was dissolved in tBuOH (10 ml) in a round bottom 
flask equipped with a magnetic stirrer bar.  A soluti n of NaClO2 (640 mg, 12.28 mmol) 
and NaH2PO4.H2O (640 mg, 16.32 mmol) in distilled H2O (6 ml) was added over 5 min.  
The reaction mixture was stirred vigorously for 3 h at RT.  The solution was dried over 
anhydrous MgSO4, filtered and the mixture was absorbed on dry silica via a rotary 
evaporator.  The silica-adsorbed material was chromat graphed on silica gel, initially 
eluting with several bed volumes of diethyl ether, followed by MeOH to elute a bright 
yellow band.  The solvent was removed using a rotary evaporator and rhein (2.31) was 
obtained as a bright yellow solid (151 mg, 0.53 mmol, 95%).   
 
Rhein (2.31): Pale yellow powder; UV (MeOH)  λMax (log ε) : 257 (2.56), 285 (2.17), 432 
(2.32) nm; IR νmax (KBr) :.  3435, 2892, 1699, 1675, 1630, 1470, 1398, 1269, 1217, 1 67 
cm-1; 1H NMR (500 MHz, DMSO-d6): δH 7.41 (1H, dd, J = 8.4, J = 1.1 Hz, H-7), 7.75 (1H, 
dd, J = 7.5, J = 1.1 Hz, H-5), 7.78 (1H, d J = 1.7 Hz, H-2), 7.84 (1H, t J = 8.3 Hz, H-6), 
8.15 (1H, d, J = 1.6 Hz, H-4), 11.90 (2H, br s, D2O exchangeable, OH-1, OH-8); 
13C NMR 
(500 MHz, DMSO-d6): δC 116.81 (C-8a), 118.80 (C-4), 119.50 (C-1a), 119.46 (C-5), 
120.02 (C-9a), 124.14 (C-2), 124.62 (C-7), 137.62 (C-6), 161.11  (C-1), 161.44 (C-8), 
165.46 (C-11), 161.43 (C-1), 191.87 (C-10), 192.75 (C-9); HR-TOF-MS: m/z 283.0249 
[M-H] - (calculated for C15H7O6, 283.0243).   
 
2.6.15 Attempted Bromination of Aloe-emodin (2.25) 
 
A round bottom flask, equipped with magnetic stirrer, was charged with CuBr (1.3 mg, 
0.009 mmol), 1,10-phenantholine monohydrate (3.6 mg, 0.018 mmol), Cu powder (35 mg, 
0.55 mmol), Fe powder (51 mg, 0.91 mmol) and CBr4
36 (242 mg, 0.73 mmol).  Aloe-
emodin (3.23) (50 mg, 0.185 mmol) in dry CH3CN (5 ml) was added to the reaction flask 
and the resulting solution was stirred vigorously for 4 h under an atmosphere of N2.  TLC 



















Aloe-emodin (2.25) (200 mg, 0.7 mmol) and PPh3 (1.00 g, 3.8 mmol) were dissolved in 
dry THF (10 ml) in a round bottom flask equipped with a magnetic stirrer bar.  CBr4 (1.4 g, 
4.2 mmol) was added and the mixture was stirred for 12 h under an atmosphere of N2 at 
RT.  The bright orange solution was dried on anhydrous MgSO4, filtered and absorbed to 
dry silica via a rotary evaporator.  The silica-absor ed material was chromatographed on 
silica gel, eluting with a diethyl ether-petroleum ether [15:10 (v/v)] running phase.  The 
solvent was removed using a rotary evaporator and the desired product was obtained as a 
bright yellow solid (210 mg, 0.63 mmol, 90%) 
 
11-Bromochrysophanol (2.33): Bright orange crystals; UV (MeOH)  λMax (log ε) : 257 
(2.27), 287 (1.99), 312 (1.73) nm; IR νmax (neat) :. 2921, 1983, 1728, 1669, 1623, 1603, 
1567, 1476, 1377, 1202, 1125 cm-1; 1H NMR (500 MHz, DMSO-d6): δH 4.81 (2H, s, H-11) 
7.40 (1H, dd, J = 8.32, J = 1.2 Hz, H-7), 7.47 (1H, d, J = 1.6 Hz, H-2), 7.73 (1H, dd, J = 
7.5, 1.1 Hz, H-5), 7.79 (1H, d, J = 1.7 Hz, H-6), 7.81 (1H, t J = 8.3 Hz, H-6), 11.91 (2H, 
br s, D2O exchangeable, OH-1, OH-8).
13C NMR (500 MHz, DMSO-d6): δC 25.1 (C-11), 
114.5 (C-9a), 115.9 (C-8a), 117.1 (C-5), 119.4 (C-4), 120.7 (C-7), 124.4 (C-2), 133.2 (C-
4a), 133.4  (C-5a), 137.4 (C-6), 153.7 (C-3), 161.4 (C-8), 161.6 (C-1) 181.6 (C-10), 191.7 
(C-9).  HR-TOF-MS: m/z 330.9613 [M-H]- (calculated for C15H8O4Br





















BuLi (2.37) (1.2 ml, 12.0 mmol) was added to freshly distilled pyrrolidine (1.0 ml, 12.0 
mmol) in dry THF (5 ml) under N2 at 0 
oC.  After being stirred vigorously for 30 min at 
RT, 11-bromochrysophanol (2.33) (140 mg, 0.42 mmol) in dry THF (15 ml) was added.  
The deep purple mixture was stirred for 12 h at RT before being acidified with conc. HCl.  
This was followed by the addition of NaHCO3 until the solution was neutralized.  The 
solvent was removed via a rotary evaporator and the resulting solid material was 
chromatographed on a silica column eluting with ethyl acetate.  11-(Pyrrolidin-1-
yl)chrysophanol (2.34) was collected as a brown residue (110 mg, 0.34 mmol, 80%). 
 
11-(Pyrrolidin-1-yl)chrysophanol (2.34): Orange solid; UV (MeOH)  λMax (log ε) : 269 
(3.10), 272 (2.74), 322 (4.20), 429 (2.68) nm; IR (KBr) νmax:. 3417, 2936, 2924, 1672, 
1628, 1570, 1353, 1352, 1215, 1159 cm-1; 1H NMR (DMSO-d6, 400 MHz): δH 1.74 (4H, 
m, H-2’), 2.54 (4H, m, H-1’), 3.75 (2H, d, H-11), 7.31 (1H, d, J = 1.1 Hz, H-2), 7.36 (1H, 
dd, J = 8.2 Hz, J = 1.1 Hz, H-7), 7.69 (1H, d, J = 1.1 Hz, H-4), 7.72 (1H, dd, J = 7.9 Hz, J 
= 1.2 Hz, H-5), 7.78 (1H, t, J = 8.3 Hz, H-6) 11.80 (2H, br s, D2O exchangeable, OH-1, 
OH-8).13C NMR (DMSO-d6, 400 MHz): δ 25.66 (C-2’), 54.01 (C-1’), 59.21 (C-11), 
115.23 (C-9a), 116.38 (C-8a), 119.80 (C-4), 119.88 (C-5), 123.77 (C-2), 124.88 (C-7), 
133.68 (C-4a), 133.80 (C-5a), 137.82 (C-6), 150.09 (C-3), 161.82 (C-1), 162.04 (C-8), 

















BuLi (2.37) (1.15 ml, 11.6 mmol) was added to freshly distilled piperidine (1.0 ml, 11.6 
mmol) in dry THF (5 ml) under N2 at 0 
oC.  After being stirred vigorously for 30 min at 
RT, 11-bromochrysophanol (2.33) (140 mg, 0.42 mmol) in dry THF (15 ml) was added.  
The deep purple mixture was stirred for 12 h at RT before being acidified with conc. HCl.  
This was followed by the addition of NaHCO3 until the solution was neutralized.  The 
solvent was removed via a rotary evaporator and the resulting solid material was 
chromatographed on a silica column eluting with an ethyl acetate mobile phase.  11-
(piperidin-1-yl)chrysophanol (2.35) was collected as a brown precipitate (108 mg, 0.32 
mmol, 75%). 
 
11-(Piperidin-1-yl)chrysophanol (2.35): brown solid; UV (MeOH)  λMax (log ε) : 268 
(1.38), 285 (0.97), 346 (0.16), 429 (0.74) nm; IR (KBr) νmax:.2929, 1672, 1632, 1570, 
1469, 1452, 1425, 1370, 1279, 1162 cm-1; 1H NMR (CDCl3, 400 MHz): δH 1.43 (2H, m, H-
3’), 1.58 (4H, m, H-2’), 2.41 (4H, m, H-1’), 3.55 (2H, s, H-11), 7.28 (1H, dd, J = 8.0 Hz, J 
= 1.1 Hz, H-7), 7.34 (1H, d, J = 1.1 Hz, H-2), 7.63 (1H, t J = 8.3 Hz, H-6), 7.80 (1H, d, J 
= 1.1 Hz, H-4), 7.82 (1H, dd, J = 8.1 Hz, J = 1.1 Hz, H-5) 12.05 (2H, br s, D2O 
exchangeable, OH-1, OH-8).13C NMR (CDCl3, 400 MHz): δC 24.2 (C-3’) 25.9 (C-2’), 54.7 
(C-1’), 63.1 (C-11), 100.1 (C-7), 114.9 (C-9a), 115.9 (C-8a), 119.5 (C-5), 120.7 (C-4), 
124.1 (C-2), 133.4 (C-4a), 133.8 (C-5a), 137.0 (C-6), 149.6 (C-3), 162.5 (C-1), 162.8 (C-
8), 181.9 (C-10), 192.6 (C-9).  HR-TOF-MS: m/z 336.1223 [M-H]- (calculated for 

















BuLi (2.37) (1.1 ml, 11.5 mmol) was added to freshly distilled morpholine (2.38) (1.0 ml, 
11.5 mmol) in dry THF (5 ml) under N2 at 0 
oC.  After being stirred vigorously for 30 min 
at RT, 11-bromochrysophanol (2.33) (140 mg, 0.42 mmol) in dry THF (15 ml) was added.  
The deep purple mixture was stirred for 12 h at RT before being acidified with conc. HCl.  
This was followed by the addition of NaHCO3 until the solution was neutralized.  The 
solvent was removed via a rotary evaporator and the resulting solid material was 
chromatographed on a silica column eluting with diethyl ether.  11-(Morpholin-1-
yl)chrysophanol (2.36) was collected as a dull orange solid (128 mg, 0.38 mmol, 90%). 
 
11-(Morpholin-1-yl)chrysophanol (2.36): Orange solid; UV (MeOH)  λMax (log ε) : 270 
(2.23), 272 (1.96), 338 (0.24), 429 (1.52) nm; IR (KBr) νmax:. 2844, 2855, 1672, 1619, 
1576, 1467, 1347, 1291, 1206, 1111 cm-1; 1H NMR (DMSO-d6, 400 MHz): δH 2.40 (4H, 
m, H-1’), 3.60 (2H, d, H-11), 3.61 (4H, m, H-2’), 7.32 (1H, d, J = 1.1 Hz, H-2), 7.37 (1H, 
d, J = 8.2 Hz, H-7), 7.69 (1H, d, J = 1.1 Hz, H-4), 7.70 (1H, d, J = 7.9 Hz, H-5), 7.78 (1H, 
t, J = 8.3 Hz, H-6) 11.80 (2H, br s, D2O exchangeable, OH-1, OH-8).
13C NMR (DMSO-d6, 
400 MHz): δC 53.6 (C-1’), 62.0 (C-11), 66.7 (C-2’), 115.3 (C-9a), 116.4 (C-8a), 119.8 (C-
4), 120.1 (C-5), 124.1 (C-2), 124.9 (C-7), 133.7 (C-4a), 133.8 (C-5a), 137.8 (C-6), 149.6 
(C-3), 161.8 (C-1), 161.9 (C-8), 181.9 (C-10), 194.3 (C-9).  HR-TOF-MS: m/z 338.1033 
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Connective tissues, such as cartilage, are crucial to maintain the healthy structure and 
efficient functioning of the body.  Matrix metalloproteinases (MMPs) are calcium-
dependent zinc-containing endopeptidases that are responsible for the controlled 
degradation of many components of the extracellular m trix (ECM), including cartilage 
tissue1.  Release of these enzymes is usually finely regulated.  However, sometimes, this 
control is altered or lost, resulting in excessive tissue breakdown at an unbalanced 
replacement build-up rate, leading to medical conditions such as osteoarthritis, tumour 
growth and metastasis, and periodontal disease.  Developing proteinase inhibitors that are 
therapeutically active is a challenging problem.  Tetracylines, such as doxycycline (3.1) 
and minocycline (3.2), are examples of a class of MMP inhibitors that are used clinically to 





















                                         (3.1)                                          (3.2) 
 
The most interesting biological property of aloin (3.3), as far as this investigation is 
concerned, is its reported ability to inhibit granulocyte MMP-8.  Aloin (3.3), which is a 
naturally occurring C-glucoside anthrone, also has many structural featur s similar to that 
of doxycycline (3.1), suggesting similar activity with regard to MMP inh bition2.  Thus, 
aloin (3.3), and its synthetic derivatives (see Chapter 2) were screened for their ability to 
inhibit MMP-2 and MMP-9, the two most prominent MMPs in mammalian blood.  Their 
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inhibitory activity, if any at all, will be compared to that of known MMP inhibitors such as 
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Matrix metalloproteinases are a family of potent enzymes that can degrade different 
components of the ECM.  Thus, they are involved in numerous biological processes.  
These include: embryonic development, blastocyst implantation, organ morphogenesis, 
nerve growth, ovulation, cervical dilatation, postpartum uterine involution, endometrial 
cycling, hair follicle cycling, bone remodelling, wound healing, angiogenesis and 
apoptosis3.  The pathological roles include roles in arthritis, cancer, cardiovascular disease, 
nephritis, neurological disease, breakdown of brain blood barrier, periodontal disease, skin 
ulceration, gastric ulcer, corneal ulceration, liver fibrosis, emphysema and fibrotic lung 
disease3. 
  
3.2.2 Structural Diversity of MMPs 
 
The complete set of MMPs produced by human cells ha been defined due to the 
sequencing of the complete human genome4.  Twenty-four distinct genes have been found 
to encode members of the MMP family.  These enzymes ar  classified based on their 
structural design, rather than their substrate specificities (Fig. 3.1).  Structurally, MMPs are 
organized around a conserved catalytic domain, which contains a propeptide that is 
necessary to maintain enzyme latency.  There is also a ignal peptide which directs their 
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secretion from the cell, and in most MMPs, a C-terminal hemopexin domain which 




















Figure 3.1.  Structural classification of human MMPs based on their domain organization4.   
 
Since these enzymes consist of similar domains (Fig. 3.1), they contain many common 
properties: (i) they are secreted as inactive zymogens; (ii) their activation can be achieved 
proteolytically or by treatment with mercurial compounds; (iii) they contain a zinc catalytic 
centre; (iv) the active enzymes function at neutral pH and require calcium for activity; and 
(v) the active enzymes are inhibited by tissue-inhibitors of metalloproteinases (TIMPs)1. 
 
There are four main groups of the MMP family; (i) the stromelysins; (ii) the collagenases; 
(iii) the gelatinases and (iv) the membrane type-MMPs (MT-MMPs).  Each member of the 
MMP family has been allocated a MMP number and the different numbers, molecular 
weights (Mr), substrate specificities and common names are listed n Table 3.1. 
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TABLE 3.1 The MMP Family-Names, Numbers, Molecular Weights (kDa)* and Known 
Matrix Substrates5 
 




Collagen type I, II, III, VI, X, gelatin, 
aggrecan, proteoglycan link protein, 
tenascin, entactin, α1-proteinase 





Collagen type I, II, III, V, VII, VIII, X, 
gelatin, aggrecan, α1-PI, α2-antiplasmin 
and fibronectin 
Collagenase-3 MMP-13 60/48 
Collagen type I, II, III, IV, VII, X, 
gelatin, plasminogen activator inhibitor 
2, aggrecan and tenascin 
Collagenase-4 MMP-18 55/42 Collagen type I and gelatin 
The Gelatinases 
Gelatinase-A MMP-2 72/66 
Collagens type I, IV, V, VII, X, XI, 
XIV, gelatin type I, II, III, fibronectin, 
elastin, vitronectin, aggrecan, link 
protein, α1-PI and activates MMP-9 and 
MMP-13a 
Gelatinase-B MMP-9 92/86 
Collagens type III, IV, V, gelatin type I, 
V, aggrecan, elastin, fibronectin, link 
protein and α1-PI. 
The Stromelysins 
Stromelysin-1 MMP-3 57/45 
Proteoglycan, link protein, fibronectin, 
laminin, elastin, gelatins type I, III, IV, 
V, collagens III, IV, V, IX, α1-PI, α2-M 
and activates MMP-1, -7, -8, -9, and -
13 
Stromelysin-2 MMP-10 57/54 
Gelatins type I, III, IV, V, collagens 
types III, IV, V, fibronectin, aggrecan, 
elastin, fibronectin and activates MMP-
1 and MMP-8 
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Stromelysin-3 MMP-11 51/44 
α1-PI  and N-terminal domain cleaves 
casein 
The Membrane-Bound MMPs 
MT MMP-1 MMP-14 66/56 
Collagens type I, II, III, IV, gelatin, 
elastin, aggrecan, proteoglycan, 
fibronectin, vitronectin and activates 
MMP-2 and MMP-13 
MT MMP-2 MMP-15 72/60 
Collagens type I, II, gelatin, 
fibronectin, tenascin, laminin, 
proteoglycan, and activates MMP-2 
MT MMP-3 MMP-16 64/52 
Activates MMP-2 and possibly other 
MMPs 
MT MMP-4 MMP-17 57/63 Gelatin 
MT MMP-5 MMP-24 63/45 
Gelatin, fibronectin, proteoglycan and 
activates MMP-2 
MT MMP-6 MMP-25 63/? Activates MMP-2, MMP-9 and α1-PI 
Other Enzymes 
Matrilysin MMP-7 28/19 
Collagens type IV, X, gelatins type I, 
III, IV, V, proteoglycan, fibronectin, 
aggrecan, link protein, tenascin, 
laminin, elastin, entactin, α1-PI and 
activates MMP-1, -2 and -9. 
Metalloelastase MMP-12 54/45,22 
Collagen type IV, elastin, gelatin, α 1-
PI, fibronectin, vitronectin and laminin 
- MMP-19 54/45 Aggrecan 
Enamelysin MMP-20 54/22 Not known 
XMMP MMP-21 70/53 Gelatin 
CMMP MMP-22 52/43 Gelatin 
- MMP-23 ?/? Not known 
Endometase MMP-26 28/? Gelatin and α1-PI 
 




3.2.3 Control of the Matrix MMPs 
 
Due to the potent proteolytic nature of MMPs, they are carefully controlled.  Control of 
activity is regulated at a number of points: (i) at the synthetic level of cytokines and growth 
factors; (ii) at the secretion level by secretion of pro-MMPs; (iii) via regulation of 





Pro-Collagenases Active Collagenases Collagen Destruction
TIMPs
Activating Enzymes






Figure 3.2.  Levels of MMP control using collagenase as an example1.   
 
3.2.3.1 Synthesis and Secretion of MMPs 
 
MMPs are secreted by a variety of connective tissue and pro-inflammatory cells including 
fibroblasts, osteoblasts, endothelial cells, macrophages, neutrophils and lyphocytes6.  The 
pro-inflammatory cytokines interleukin-1 (IL-1) and tumour necrosis factor-α (TNF-α) 
stimulate numerous cell types, including chondrocytes, to secrete both collagenase and 
stromelysin7.  Recent studies have shown that direct contact between T-lymphocytes and 
monocytes is a major pathway to up-regulate MMP biosynthesis and factors produced by 
T-cells can also increase collagenase synthesis by dermal fibroblasts8.   
 
3.2.3.2 Activation of the Proenzymes 
 
All MMPs are secreted in a proenzyme (zymogen) form.  A propeptide, containing a 
conserved sequence PRCGVPD, is lost during activation.  A cysteine residue is attached to 
the catalytic zinc ion, and disruption of this interaction initiates activation9.  Complete in 
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vivo activation is achieved by removal of the propeptide proteolytically, either 
autocatalytically or by other proteinases.  The active enzyme can now bind to its substrate, 
and the zinc ion at the active site can hydrolyse susceptible bonds in the protein 
substrates10. 
 
3.2.3.3 Inhibition of Active Enzymes 
 
Active MMPs are inhibited by TIMPs, which are found connective tissue11.  TIMP-1 is a 
28-kDa glycoprotein held by 6 disulfide bonds to form two main domains.  The protein is 
highly stable to both low pH and temperature.  The mechanism of inhibition by TIMP-1 is 
unknown.  The inhibitor binds tightly to the active forms of MMPs in a 1:1 ratio12.  TIMPs 
play an important role in controlling connective tissue breakdown by blocking the action of 
the activated MMPs and also preventing activation of the proenzymes13. 
 
3.2.4 The Gelatinases: MMP-2 and MMP-9 
 
These two MMPs are the most abundant enzymes of the family, occurring prominently in 
mammalian blood.  MMP-2 (Fig. 3.3) and MMP-9 (Fig. 3.4) play a crucial role in the 
breakdown of the extracellular matrix during cell migration and tissue remodelling14.  The 
gelatinases are also indicated in a growing number of chronic chromic cardiovascular 
pathologies including heart failure, atherosclerosis and abdominal aneurysms.  MMP-2 has 
also recently been implicated in many acute cardiovascular processes such as: platelet 
aggregation, regulation of vascular tone and modulation of the inflammatory response15.  













Figure 3.4.  Structure of MMP-918. 
 
3.2.5 Prospects for the Therapeutic Inhibition of MMPs 
 
MMPs have been heralded as promising targets for cancer therapy, and consequently a 
large number of natural and synthetic MMP inhibitors have been identified as cytostatic 
and anti-angiogenic agents.  Many of these compounds have begun to undergo clinical 
trials6.  Creating proteinase inhibitors that are therapeutically active is a daunting task.  
Besides having the required potency, the compound needs to be bioavailable, preferably 
after oral dosing.  After administration, the drug must enter the circulation and reach the 
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desired concentration in the tissues.  The compound must be specific for the target enzyme 
family and must not be antigenic.  Any toxic side eff cts should also be eliminated19. 
 
3.2.6 Design of MMP Inhibitors 
 
The direction that has been employed in the design of i hibitors is to select a zinc chelating 
ligand and attach it to a peptide that mimics the cl avage site in the MMPs target 
substrates1.  Therefore, metalloproteinase inhibitors can be based on: (i) substrate cleavage 
sites20; (ii) sites cleaved in proteinase inhibitors21; (iii) inhibitory sequences such as the 
propeptide zinc-binding region22 and (iv) sequences cleaved during activation of one MMP 
by another21.  It has been suggested that the principle of MMP inhibition should initially be 
tested with broad-spectrum inhibitors to determine the potential of these compounds.   
 
3.2.6.1 Tetracyclines as Inhibitors of MMP 
 
The antibiotic tetracycline (3.4) and related compounds, such as doxycycline (3.1) and 
minocycline (3.2), exhibit inhibitory activity against collagenase, although the mechanism 
of inhibition is unknown.  These tetracyclines have MMP inhibitory activity that is distinct 
from their antimicrobial property.  These compounds are already in clinical use, and may 
give valuable information on MMP inhibition1.  Doxycycline (3.1) is the most potent 
inhibitor of MMPs in this class of compounds, and has been shown to interact with Ca2+ 
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3.3 Results and Discussion 
 
3.3.1 Western Blot of MMP-2 and MMP-9 
  
A western blot was used to confirm the identity of MMP-2 and MMP-9 in the horse serum, 
using primary antibodies (rabbit anti-MMP-2 and chicken anti-MMP-9) that bind 
specifically to MMP-2 and MMP-9.  Specific enzyme-linked secondary antibodies (anti-
rabbit IgG alkaline phosphatase conjugate for MMP-2 and anti-chicken IgG alkaline 
phosphatase conjugate for MMP-9) and an appropriate substrate (BCIP and NBT) were 
used.   
 
                                                                          
                                         (A)          (B)                                       (C) 
 
Figure 3.5.  Western blots of control (A) of MMP-2 in horse serum, showing a negative 
result for MMP-2 in the absence of a MMP-2 pre-immune antibody, horse serum sample 
(B) displaying a positive result for the presence of MMP-2 in the presence of an MMP-2 
pre-immune antibody and blot (C) is a lane containing Mr markers. 
 
The Western blot for MMP-2 (B) which was treated with MMP-2 pre-immune shows 
specificity of the primary antibody for MMP-2, at 66 kDa [determined by a Mr marker 
(C)], confirming the presence of MMP-2 in horse serum (Fig. 3.5).  Omission of the MMP-
2 pre-immune antibody during preparation showed no bands (A). 
 
MMP-2 (66 kDA)    
phosphorylase B  (97 kDa)
bovine serum albumin  (68 kDa)
ovalbumin  (45 kDa)
carbonic anhydrase  (30 kDa)
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                                       (A)             (B)                                        (C) 
 
Figure 3.6.  Western blots of control (A) of MMP-9 in horse serum, showing a negative 
result for MMP-9 in the absence of a MMP-9 pre-immune antibody, horse serum sample 
(B) displaying a positive result for the presence of MMP-9 in the presence of an MMP-9 
pre-immune antibody and blot (C) is a lane containing Mr markers. 
 
The Western blot for MMP-9 (B) which was treated with MMP-2 pre-immune shows 
specificity of the primary antibody for MMP-9, at 94 kDa [determined by a Mr marker 
(C)], confirming the presence of MMP-9 in horse serum (Fig. 3.6).  Omission of the MMP-




Aloin (3.3) and synthetic derivatives were screened for their possible gelatinolytic 
inhibitory characteristics, using zymography (see Section 3.5.1.2), against horse serum 
MMP-2 and MMP-9. The compounds were applied at concentrations ranging from 10 mM 
to 0.05 mM. EDTA, a strong zinc chelator, was used as an indication of complete enzyme 
inhibition. The inhibitory activity of aloin (3.3) and derivatives was compared to that of 
doxycycline (3.1), used clinically as a MMP inhibitor. Proteolytic a tivity was indicated by 
the presence of clear bands on a dark background and the intensity of the band being 
proportional to the MMP-2 and MMP-9 activity.  
 
MMP-9 (94 kDA)     
phosphorylase B  (97 kDa)
bovine serum albumin  (68 kDa)
ovalbumin  (45 kDa)
carbonic anhydrase  (30 kDa)
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                                                         A       B       C 
 
Figure 3.7. Positive control (A) zymogram in gelatinase buffer showing native activity of 
MMP-9 and MMP-2 in horse blood, negative control (B) zymogram in gelatinase buffer 
containing EDTA, displaying complete inhibition of MMP-9 and MMP-2 and gel (C) is a 
lane containing Mr markers. 
 
The identity of both MMP-9 and MMP-2 were confirmed by their Mr, judged using Mr 
markers (Fig. 3.7) and a western blot (see S ction 3.3.1).   The positive control (A) served 
as a reference for the subsequent zymograms containing potential MMP-2 and MMP-9 
inhibitors derived from aloin.  The negative control (B) contains EDTA, which binds 
strongly to the catalytic zinc ion and other ions i the MMPs structure.  This results in the 
inhibition of MMP activity, indicating what would be observed in the absence of MMP 
activity and confirms the identity of the enzymes being metalloproteinases.  Cathepsins, 
enzymes also capable of gelatinase activity, are also occasionally found in mammalian 
serum23.  Since no activity was observed in the presence of EDTA, it can be concluded that 












MMP-2 (66 kDA)    
MMP-9 (94 kDA)     
phosphorylase B  (97 kDa)
bovine serum albumin  (68 kDa)
ovalbumin  (45 kDa)






3.3.2.1 Doxycycline (3.1) Zymograms 
 
               
                                        10       5.0    2.5   1.0   0.5   0.25  0.1   0.05 
 
Figure 3.8.  Zymograms displaying the effect of various doxycyline (3.1) concentrations, 
i.e. from 10 mM to 0.05 mM incorporated into the gelatinase buffer.   
 
Doxycycline (3.1) inhibits both MMP-2 and MMP-9 at concentrations of 10 mM and 5 
mM.  Activity is restored when concentrations are dopped to 2.5 mM to 0.05 mM (Fig. 
3.8). 
 
3.3.2.2 Aloin (3.3) Zymograms 
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Figure 3.9.  Zymograms displaying the effect of various aloin (3.3) concentrations, i.e. 
from 10 mM to 0.05 mM incorporated into the gelatinse buffer.   
 
Aloin (3.3) inhibits both MMP-2 and MMP-9 at a concentration f 10 mM.  MMP-2 and 
MMP-9 activity is partially restored at aloin (3.3) concentrations of 5.0 mM to 1.0 mM 
(Fig. 3.9).  Complete MMP-2 and MMP-9 activity is restored at aloin (3.3) concentrations 

















               
                                    10     5.0    2.5     1.0      0.5   0.25     0.1   0.05 
 
Figure 3.10.  Zymograms displaying the effect of various homonataloin (3.5) 
concentrations, i.e. from 10 mM to 0.05 mM incorporated into the gelatinase buffer.   
 
Homonataloin (3.5) displays slight inhibitory activity of both MMP-2 and MMP-9 at 
concentrations of 10 mM to 5.0 mM (Fig. 3.10).  Complete MMP-2 and MMP-9 activity 
was restored from homonataloin (3.5) concentrations of 2.5 mM to 0.05 mM. 
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Figure 3.11.  Zymograms displaying the effect of various aloe-emodin (3.6) 
concentrations, i.e.,from 10 mM to 0.05 mM incorporated into the gelatinase buffer.  Aloe-
emodin (3.6), which was virtually insoluble in the gelatinase buffer, displayed no 
inhibitory effects on neither MMP-2 nor MMP-9 at aloe-emodin (3.6) concentrations at10 
mM to 0.05 mM (Fig. 3.11).   
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Figure 3.12.  Zymograms displaying the effect of various nataloe-emodin (3.7) 





Nataloe-emodin (3.7) shows high inhibition of MMP-2 and moderate inhibition of MMP-9 
at 10 MM and 5.0 mM inhibitor concentrations (Fig. 3.12).  The activity of both MMP-2 
and MMP-9 is slightly reduced at a nataloe-emodin co centration of 2.5 mM.  Complete 
MMP-2 and MMP-9 activity is restored from nataloe-emodin (3.7) concentrations of 1.0 
mM to 0.05 mM. 
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Figure 3.13.  Zymograms displaying the effect of various rheinal (3.8) concentrations, i.e. 
from 10 mM to 0.05 mM incorporated into the gelatinse buffer.   
 
Rheinal (3.8) shows high inhibition of MMP-2 and moderate inhibition of MMP-9 at 10 
MM and 5.0 mM inhibitor concentrations (Fig. 3.13).  The activity of both MMP-2 and 
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Figure 3.14.  Zymograms displaying the effect of various rhein (3.9) concentrations, i.e. 
from 10 mM to 0.05 mM incorporated into the gelatinse buffer.   
 
Rhein (3.9) displayed no inhibitory effects on neither MMP-2 nor MMP-9 at rhein (3.9) 
concentrations at 10 mM to 0.05 mM (Fig. 3.14).   
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Figure 3.15.  Zymograms displaying the effect of various 11-(pyrrolidin-1-
yl)chrysophanol (3.10) concentrations, i.e. from 10 mM to 0.05 mM incorporated into the 
gelatinase buffer.   
 
11-(Pyrrolidin-1-yl)chrysophanol (3.10) displayed no inhibitory effects on neither MMP-2 
nor MMP-9 at 11-(pyrrolidin-1-yl)chrysophanol (3.10) concentrations from 10 mM to 0.05 
mM (Fig. 3.15).   
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Figure 3.16.  Zymograms displaying the effect of various 11-(piperidin-1-yl)chrysophanol 




11-(Piperidin-1-yl)chrysophanol (3.11) at concentrations of 10 mM to 1.0 mM showed 
remarkably high selective inhibition of MMP-2.  The activity of MMP-2 was restored from 
11-(piperidin-1-yl)chrysophanol (3.11) concentrations of 0.5 mM to 0.05 mM (Fig. 3.16).  
MMP-9 activity was unaffected at all concentrations of 11-(piperidin-1-yl)chrysophanol 
(3.11). 
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Figure 3.17.  Zymograms displaying the effect of various 11-(morpholin-1-
yl)chrysophanol (3.12) concentrations, i.e. from 10 mM to 0.05 mM incorporated into the 
gelatinase buffer.   
 
11-(Morpholin-1-yl)chrysophanol (3.11), at concentrations of 10 mM to 5.0 mM displayed 
high inhibition of MMP-2.  Strangely, at 11-(morpholin-1-yl)chrysophanol (3.11) 
concentrations of 2.5 mM to 0.5 mM, MMP-2 activity was fully restored, only to diminish 
again at 11-(morpholin-1-yl)chrysophanol (3.11) concentrations of 0.25 mM to 0.05 mM.   
This effect is possibly attributed to experimental error.  MMP-9 activity was unaffected at 




3.3.2 Inferences and Discussion of Zymograms 
 
A study by Barrentes and Guinea2 reported that aloin (3.3) displayed good inhibitory 
properties against Clostridium histolyticum collagenase (ChC) and granulocyte MMP-8.  
The inhibitory action of aloin was compared to that of doxycycline (3.1), a structurally 
similar anthraquinone that is a well known broad range MMP-inhibitor.  The anthrones 
aloin (3.3) and homonataloin (3.5) and their synthetic derivatives, which were either 
isolated or synthesized, have never been tested for their possible inhibitory activity against 
MMP-2 and MMP-9.  These two enzymes play essential regulatory roles in the body, but 
are also involved in a growing number of pathological onditions15,16.  Most MMP-2 and 
MMP-9 inhibitors target the zinc ion in the enzymes catalytic site5.  The action of 
doxycycline (3.1) and aloin (3.3) has been reported to proceed via a non-competitive 
mechanism2, implying that these compounds indirectly affect the zinc catalytic site.  Thus, 
studying the mode of action of this class of compounds could be very useful in designing 
new MMP-inhibitors.   
 
Aloin (3.3) and doxycycline inhibited both MMP-2 and MMP-9 at concentrations of 5 mM 
and 10 mM.  Aloin (3.3) continued to moderately inhibit these enzymes at concentrations 
of 2.5 mM and 1.0 mM.  At these concentrations for d xycycline (3.1) enzyme activity 
was completely returned, implying that aloin (3.3) displays higher MMP-2 and MMP-9 
inhibitory properties than doxycycline (3.1).   A similar result has been reported for MMP-
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The ketone at C-12 and the OH group at C-11 on the doxycyline (3.1) structure have been 
reported to be essential for activity2.   Comparing the structures of doxycycline (3.1) to the 
structure of aloin (3.3), the carbonyl group at C-9, between the hydroxyls at C-8 and C-1 
on the anthrone, is consistent with that pharmacophore profile and it seems reasonable to 
postulate that the aloin (3.3) inhibition of the MMPs is due to an interaction similar to that 
between doxycycline (3.1) and MMPs. 
 
Aloin (3.3) has a moderately high affinity for binding to calcium ions, as this is 
experimentally shown in the aloin-calcium salt formation (see Chapter 2, Section 2.3.5).  
This was used as a method of selectively precipitatng an aloin-calcium salt from the A. 
marlothii leaf exudate that contains many other chemical constituents24.  MMPs require 
Ca2+ as enzymatic cofactors that are necessary for theiract vity2.  MMPs also contain 
calcium ions within their quaternary protein structure which are vital for maintaining the 
structural integrity of these enzymes1.  Thus based on the affinity aloin (3.3) has for 
calcium ions, it can be proposed that aloin (3.3) interacts/chelates with either (i) the Ca2+ 
cofactors in solution or (ii) the calcium ions incorp rated into the MMP-structure.   These 
aloin-calcium interactions could lead to either diminished MMP activity, due to lack of 
Ca2+ cofactors, or result in a change in the structural conformation of the enzyme, 
rendering the catalytic zinc site inactive.     
 
Homonataloin (3.5) displays slight inhibition against MMP-2 and MMP-9 at high 
concentrations, i.e. at 10 mM and 5 mM.  Comparing the structures of homonataloin (3.5) 
to aloin (3.3), it can be seen that homonataloin (3.5) has a methoxy-group at C-8 compared 
to the hydroxyl-group in aloin (3.3).  This methyl-group attached to the oxygen atom at C-
8 sterically restricts interactions of the C-8 oxygen with other groups.  Since it has been 
proposed that the interaction of this C-8 oxygen atom plays a role in MMP-inhibition, it 
seems logical to assume that this methoxy-group lowers the MMP-inhibitory properties of 
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The biggest problem with using aloin (3.3) or homonataloin (3.5) as MMP-inhibitors is 
that they are unstable in solution since they are susceptible to oxidation of their sugar 
moieties25.  Thus creating aloin/homonataloin derivatives without the sugar moieties 
should greatly increase their stability in solution. 
 
Aloe-emodin (3.6) was poorly soluble in the gelatinase buffer soluti n and consequently 
showed no inhibition of MMP-2 or MMP-9 at any concetration.  Nataloe-emodin (3.7), 
which has better solubility in the gelatinase buffer than aloe-emodin (3.6), showed 
complete inhibition of MMP-2 and MMP-9 at concentrations of 10 mM, and moderate 
inhibition of these enzymes at concentrations of 5 mM and 2.5 mM.  Similarly to aloe-
emodin (3.6), rheinal (3.8), was poorly soluble in the gelatinase buffer soluti n but 
displayed good inhibition of both MMP-2 and MMP-9 at concentrations of 10 mM and 5 
mM.  In contrast, rhein (3.9) had excellent solubility in the gelatinase buffer solution yet 
failed to inhibit the MMPs at any concentration.   
 
Rhein (3.9) is the active metabolite of diacerein (3.13), which is a drug that has been used 
in clinical studies to treat to the symptoms of oste arthritis.  Rhein (3.9) has been reported 
by Tamura et al. to down-regulate the production of pro-MMPs -1, -3, -9 and -13 and up-
regulate the production of TIMPs in cultured rabbit ar icular chondrocytes26.  The exact 
mechanism of the therapeutic action of rhein on osteoarthritis is unknown, but it has not 
been reported to be an MMP-inhibitor, specifically of MMP-2 or MMP-9, which was also 
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11-(Pyrrolidin-1-yl)chrysophanol (3.10) did not show any MMP-2 or MMP-9 inhibition, 
whilst 11-(piperidin-1-yl)chrysophanol (3.11) and 11-(morpholin-1-yl)chrysophanol (3.12) 
did.  11-(Piperidin-1-yl)chrysophanol (3.11) and 11-(morpholin-1-yl)chrysophanol (3.12) 
have 6-membered nitrogen-containing rings and 11-(pyrrolidin-1-yl)chrysophanol (3.10) 
has a 5-membered nitrogen-containing ring.  Thus it can be assumed that this difference in 
ring size plays a role in the inhibition of MMP-2 and MMP-9. This difference in ring size 
is most probably influential in a peripheral ligand i teraction of the nitrogen-atom in the 6-
membered ring and a region in the protein structure. 
 
11-(Piperidin-1-yl)chrysophanol (3.11) showed selective inhibition of MMP-2 at 
concentrations of 10 mM to 1.0 mM.  Similarly, 11-(morpholin-1-yl)chrysophanol (3.12) 
selectively inhibited MMP-2 at concentrations of 10mM and 5 mM.  These results are 
highly promising as selective MMP-2 inhibition is an ttractive proposition, since MMP-2 




The inhibitory activity of aloin (3.3) and derivatives were successfully tested against 
MMP-2 and MMP-9 using zymography.  Aloin (3.3), nataloe-emodin (3.7) and rheinal 
(3.8) displayed mild inhibition against MMP-2 and MMP-9.  Homonataloin (3.5), aloe-
emodin (3.6), rhein (3.9) and 11-(pyrrodin-1-yl)chrysophanol (3.10) also showed either 
poor or no inhibition against MMP-2 and MMP-9.  11-Piperidin-1-yl)chrysophanol (3.11) 
and 11-(morpholin-1-yl)chrysophanol (3.12) displayed selective inhibition against MMP-2. 
Zymography is a qualitative biochemical technique, thus a quantitative study is also 






All the chemicals used in this biochemical component of this research project were 




3.5.1.1 Sodium Dodecyl Sulfate (SDS) Polyacrylamide Gel Electrophoresis (PAGE) 
 
Polyacrylamide gel electrophoresis enables protein s paration by differential migration to 
either the cathode or anode through a chemically inert matrix.  This matrix is comprised of 
acrylamide and N,N'-methylene bisacrylamide co-monomers that undergo a free radical 
mediated polymerization to create a meshwork of pores that sterically constrict protein 
movement.  Ammonium persulfate is the polymerization radical-initiator, and 
tetramethyethylenediamine (TEMED) (a donor and acceptor of free radicals) is the catalyst 
facilitating the process.  The molecular weight (Mr) range of protein separation is 
determined by the total acrylamide concentration (acryl mide and bisacrylamide) and the 
acrylamide : bisacrylamide ratio27.   
 
When SDS is absent, the direction and extent of protein migration depends mainly on the 
individual mass-to-charge ratios and complicates Mr determinations.  SDS partially 
denatures non-sulfide-linked oligomeric structures and the secondary structure of proteins, 
adding a nett-negative charge on the proteins due to the strongly anionic group on the 
detergent.  The micelle formed by the SDS may otherwis  be unilamellar (due to 
hydrophobic interactions) or bilamellar (due to electrostatic interactions).  The addition of 
a reducing agent (e.g. β-mercaptoethanol), combined with heating, allows the intra- and 
inter-disulfide bridges to be broken, and the polypeptide chains to be linearised by 
thermally overcoming folding kinetics.  The resulting peptide chain can bind to SDS, 
allowing protein migration in an electric field to s lely rely on the basis of Mr (assuming a 
constant SDS binding ratio).  This occurs as all the proteins now carry a nett negative 






Zymography is a SDS-PAGE gel that enables the detection of enzyme activity, after the 
proteins have been electrophoresed28.  In zymography, the resolving gel contains 
incorporated proteinase substrate (e.g. gelatin, collagen, fibrin, casein).  Substrate 
concentration is crucial for optimal band formation, resolution and detection.  Non-
reducing and non-heating conditions are used to retain enzyme activity.  The gel was 
washed with Triton X-100, after electrophoresis, to removes SDS bound to the protein and 
renature the enzyme.  The SDS become easily detached at this dilution, having a 
significantly higher critical micelle concentration (CMC) than Triton X-100 (CMCSDS = 
8.27 mM; CMCTX-100 = 0.24 mM
27).  The gel was subsequently incubated at optimal 
temperature in the appropriate buffer, which contains the necessary enzyme cofactors and 
at the optimum enzyme pH.  Enzyme activity was detect d by staining the gels with either 
a Coomassie Blue or Amido black solution.  Activity appears as clear, translucent bands 
against a stained undigested background. 
 
Zymography, using fresh horse blood, was utilized in th s study for the detection of MMP-
2 and MMP-9.  Whole blood was allowed to clot befor it was centrifuged, and the serum 
was separated from the lower red blood cell layer.  The MMP substrate chosen was gelatin, 
a substrate cleaved by a broad range of proteinases from other classes (e.g. cathepsins) in 
addition to MMP-2 and MMP-9.  MMP specificity was ensured by the use of additional 
gelatinase buffer containing EDTA 
 
Activity of these gelatinases, and not the cathepsins (if present) will be inhibited by the 
EDTA, owing to the chelation of the metal in the catalytic active site.     
 
3.5.1.3 Western Blotting 
 
Western blotting is a biochemical technique that provides information about antibody 
specificities, the target antigen, Mr, activation status (i.e. enzyme pro-form vs. active 
species), oligomeric arrangement or post-translation l modifications. 
 
The thickness of the SDS-PAGE gel and % transmittance (%T) affects the protein transfer 
time, as well the efficiency of the transfer onto the nitrocellulose membrane.  Generally a 
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thinner gel (0.1-0.5 mm) promotes better protein transfer, but may limit the amount of 
protein that can be loaded.  When a SDS-PAGE gel has a high %T, protein transfer is 
greatly hindered.  Also, if the %T of the SDS-PAGE gel is too low, band resolution and 
separation is reduced.   
 
Blocking steps prevent non-specific protein association with the nitrocellulose membrane.   
 
3.5.2 Materials and Methods 
 
3.5.2.1 SDS-PAGE Gel Reagents  
 
Acrylamide/bisacrylamide monomer stock solution (30% T, 2.67 C).  Acrylamide 
monomer (58.4 g) and N,N'-methylene bisacrylamide (1.60 g) were dissolved in d.H2O 
(200 ml).  The solution was then filtered through Watman No. 1 filter paper and stored at 
RT in an amber bottle. 
 
Running gel buffer (1.5 M Tris-HCl, pH 8.8).  Tris (36.3 g) was dissolved in d.H2O (180 
ml), titrated to pH 8.8 with HCl [30% (v/v)], and made up to 200 ml.  The solution was 
stored in a plastic bottle at 4 oC. 
 
Stacking gel buffer (500 mM Tris-HCl, pH 6.8).  Tris (12.0 g) was dissolved in d.H2O 
(180 ml), titrated to pH 6.8 with HCl (30% v/v), and made up to 200 ml.  The solution was 
stored in a plastic bottle at 4 oC. 
 
SDS stock solution [10% (w/v)].  SDS (10 g) was dissolved in d.H2O (100 ml) and stored 
at RT. 
 
Electrode buffer [25 mM Tris-HCl, 192 mM glycine, 0.1% (m/v) SDS, pH 8.3].  Tris 
(0.75 g), glycine (3.6 g), and SDS stock (2.5 ml) were dissolved in d.H2O (247.5 ml). 
 
Ammonium persulfate initiator solution [10 % (w/v)] .  Ammonium persulate (0.05 g) 
were dissolved in d.H2O (0.5 ml) and stored at 4 
oC for up to a week. 
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Non-reducing sample loading buffer [62.5 mM Tris, 10% (v/v) glycerol, 2% (w/v) 
SDS, 0.025% (w/v) bromophenol blue, pH 6.6].  Stacking gel buffer ( 1 ml), d.H2O (3.4 
ml), glycerol (1.6 ml), SDS [1.6 ml of a 10% (w/v) solution] and bromophenol, blue [0.4 
ml of a 0.5% (w/v) solution in d.H2O] were stirred together. 
 
Renaturation solution [2.5 % (v/v) Triton X-100].  Triton X-100 (6.25 ml) was 
dissolved in d.H2O (250 ml) and stored at 4 
oC. 
 
Stock gelatin solution [1% (w/v)].   Porcine skin gelatin (300 bloom) (0.1 g) was added to 
d.H2O (10 ml).  The solution was heated whilst stirring vi orously to dissolve the gelatin.   
 
Gelatinase Zymography buffer [50 mM Tris-HCl, 200 mM NaCl, 5 mM CaCl2, 0.02% 
(v/v) Brij 35, pH 7.5 at 37oC].  Tris (0.1 g), NaCl (1.17 g), CaCl2.2H2O (0.109 g) and Brij 
35 [67 µl of a 30% (v/v)] solution were dissolved in d.H2O (90 ml) and heated to 37 
oC.  
The pH was titrated to 7.5 with HCl [30% (v/v)] and the volume was made up to 100 ml. 
 
Amido Stain Stock Solution [1% (w/v)].  Amido black (1.0 g) was dissolved in d.H2O 
(100 ml) by stirring for 1 h at RT.  The solution was then filtered through Whatman no. 1 
filter paper and stored at RT. 
 
Staining Solution [0.1% (w/v) amido black, 30% (v/v) methanol, 10% (v/v) acetic 
acid].  Stain stock solution (50 ml), methanol (150 ml), acetic acid (50 ml) and d.H2O (300 
ml) were mixed together at RT. 
 
Destaining Solution [30% (v/v) methanol, 10% (v/v) acetic acid].  Methanol (150 ml), 
acetic acid (50 ml) and d.H2O (300 ml) were mixed together at RT. 
 
M r markers.  Standards for Mr determination were: phosporylase b (94 kDa), bovine 
serum albumin (68 kDa), ovalbumin (45 kDa), carbonic anhydrase (30 kDa), soybean 
trypsin inhibitor (20.1 kDa) and lysozyme (14 kDa).  The lysophilised markers were 





3.5.2.2 SDS-PAGE gel/Zymogram Procedure 
 
The SDS-PAGE electrophoresis unit (Hoefer® Mighty Small) was assembled according to 
the manufacturers’ instructions.  The glass plates, plastic combs, plastic spacers and glass 
backings were cleaned with detergent and then with acetone.  These components were then 
assembled in a gel caster. 
 
Acrylamide monomer, gel buffer, d.H2O, stock gelatin solution, SDS, ammonium 
persulfate and TEMED as indicated for the running gel (Table 3.2), were mixed together 
thoroughly.  This running gel mixture was then carefully loaded onto the gel caster 
apparatus (overlaid with d.H2O to exclude oxygen), to a depth of 2.5 cm from the top of 
the glass plate, and allowed to polymerise.  After th  running gel had set (∼45 min), the 
d.H2O was poured out and the desired stacking gel solution was made up as described in 
Table 3.2.  The stacking gel mixture was then layered on top of the polymerised running 
gel.  Plastic 10 well combs were placed into the stacking gel and polymerisation was 
allowed to occur (∼20 min).  The combs were removed and the gels were ass mbled into 
the electrophoresis apparatus.  The serum is mixed with sample loading buffer (1:6 dilution 
ratio of serum : loading buffer) and the mixture is then agitated for 10 min at RT.  
Electrode buffer was made up, added, and the samples (10 µl) were carefully loaded onto 
the gels.  During electrophoresis, the gels were cooled using a circulatory water bath (4 oC) 
and protein samples were separated at 36 mA (unlimited voltage). 
 
Table 3.2.  Reagent composition and proportions for two Tris-glycine gels containing 
0.1% (w/v) gelatin 
 
 Running gel (%) Stacking gel (%) 
Reagent 
 
12.5% 7.5% 5% 4% 3% 
Monomer (ml) 
 




3.75 3.75 3.75 - - 
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Stacking gel 
buffer (ml ) 
 
- - - 1.75 1.75 
10% SDS (µl) 
 
150 150 150 70 70 
d.H2O (ml) 
 




75 75 75 50 50 
TEMED (µl) 
 




1.475 1.475 1.475 - - 
 
Once electrophoresis was complete, the gels were carefully removed and were soaked in 
renaturation solution (2 x 30 min, RT) and shaken on an orbital shaker.  The gels were then 
rinsed in d.H2O (30 min). 
 
For gelatinase assays, the controls: (+) no inhibitor (d.H2O); (-) known inhibitors 
(doxycyline, EDTA); and potential inhibitors (aloin and derivatives) were freshly 
solubilised in the gelatinase Tris-HCl incubation buffer used for developing the zymogram.  
The gel was cut into slices corresponding to the lan s which were put in different tanks and 
incubated at 37 oC for 36 h in the incubation buffer 
 
The slabs were then stained (15-30 min) in amido black staining solution, and destained in 
the same solution without the amido black dye.  After destaining, a light translucent band 
over a blue background was detected for gelatinase activity.  The gels were then 





3.5.2.3 Western Blot Reagents 
 
Gershoni blotting buffer [ 25 mM Tris-HCl, 192 mM glycine, 20% (v/v) methanol, 
0.01% (w/v) SDS, pH 8.3].  Tris (6.05 g), glycine (28.8 g) and SDS [2 ml of a 10% (w/v) 
solution] were dissolved in d.H2O (1.6 l).  Methanol (400 ml) was added to the soluti n, 
which was stored at -20 oC. 
 
Ponceau S protein stain solution [0.1% (w/v) in 1% (v/v) acetic acid].  Ponceau S (0.1 
g) and acetic acid (1 ml) were added to a 100 ml volumetric flask and made up to volume 
with d.H2O. 
 
Tris-buffered saline (TBS: 20 mM Tris-HCl, 200 mM NaCl, pH 7.4).  Tris (2.42 g) and 
NaCl (11.69 g) were dissolved in d.H2O (950 ml).  The pH was adjusted to 7.4 with HCl 
and the volume was made up to 1 l with d.H2O. 
 
Blocking solution [5% (w/v) non-fat milk powder in TBS].  Non-fat milk powder (5 g) 
was dissolved in TBS (100 ml).   
 
Alkaline phosphatase detection buffer (50 mM Tris-HCl, 5 mM MgCl2, pH 9.5).  Tris 
(0.61 g) and MgCl2.2H2O (0.10 g) were dissolved in d.H2O (90 ml).  The pH was adjusted 
to 9.5 with HCl and the volume was made up with d.H2O. 
 
Alkaline phosphatase substrate solution [0.015% (w/v) BCIP, 0.03% (w/v) NBT in 
detection buffer].  BCIP (1.5 mg in 1 ml DMF) and NBT (3 mg) were dissolved in 
detection buffer (10 ml) just before use. 
 
MMP-2 primary (pre-immune) antibody [L43 Cat P1 (20 µg/ml)].  L43 Cat P1 [14 µl 
of a 17.32 mg/ml stock solution] was dissolved in TBS (12 ml) just before use. 
 
MMP-2 primary (immune) antibody (20 µg/ml).  Rabbit anti-MMP-2 primary antibody 
[12 µl of a 19.76 mg/ml stock solution] was dissolved in TBS (12 ml) just before use. 
 
MMP-9 primary (pre-immune) antibody [L43 Cat P1 (20 µg/ml)].  L43 Cat P1 [34 µl 
of a 7.00 mg/ml stock solution] was dissolved in TBS (12 ml) just before use. 
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MMP-9 primary (immune) antibody (20 µg/ml).  Chicken anti-MMP-9 primary 
antibody [16 µl of a 15.04 mg/ml stock solution] was dissolved in TBS (12 ml) just before 
use. 
 
MMP-2 secondary antibody [anti-rabbit IgG alkaline phosphatase conjugate].  MMP-
2 secondary antibody [1 µl of a mg/ml stock solution] was dissolved in TBS (150 ml) just 
before use. 
 
MMP-9 secondary antibody [anti-chicken IgG alkaline phosphatase conjugate].  
MMP-9 secondary antibody [1 µl of a mg/ml stock solution] was dissolved in TBS (30 ml) 
just before use. 
 
3.5.2.4 Western Blot Procedure 
 
Following SDS-PAGE (Section 3.4.2.2), the gel was removed from the electrophoresis 
unit, and submerged (30 min) in ice-cold transfer buffer together with HybondTM-C 
nitrocellulose hybridization transfer membrane (0.45 µm) and Whatman filter paper.  The 
transfer cassette (Hoefer® TE Series Transphor Electrophoresis Unit) was assembled and 
orientated in the electrophoresis chamber to ensure that the membrane was closest to the 
anode.  The chamber was filled with ice-cold transfer buffer and stirred with a magnetic 
stirrer continuously.  Protein transfer was performed at a constant current of 90 mA for 18 
h.  The gel and transfer membrane were then carefully removed from the cassette, and the 
outline of the gel was marked onto the membrane.  The nitrocellulose membrane was 
rinsed with d.H2O and then stained with Ponceau S to visualize the Mr markers, the sample 
protein profiles and to assess the efficiency of the transfer.  The positions of the lanes and 
the markers were marked by pricking the membrane gently with a needle point.  The 
Ponceau S was decolourised with TBS and the membrane w s air-dried before probing. 
 
The membrane was incubated (1 h, 10 ml/lane) with blocking solution to prevent non-
specific adsorption of antibodies.  The membrane was then washed in TBS (3 x 5 min, 10 
ml/wash) and incubated with the appropriate primary ntibody (2 h, 10 ml/lane).  
Following washing in TBS (3 x 5 min, 10 ml/wash), the membrane was incubated with the 
appropriate enzyme conjugated secondary antibody (1 h, 10 ml/lane).  The membrane was 
washed as previously, immersed in the appropriate substrate solution (10 ml/lane) and 
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developed (5-10 min) until distinct bands were observed against a lightly coloured 
background.  The membrane was rinsed with d.H2O, dried and stored in the dark until 
photographed. 
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Malaria affects 300-500 million people annually and 0.5-2.5 million people die from the 
disease1.  The rapid spread of malaria together with the emergence of resistance against 
conventional anti-malarial drugs has put enormous pressure on public health systems to 
introduce new treatments.  Chloroquine (4.1) and artemisinin derivatives are currently the 
two most widely used classes of antimalarials.  Artemisinin (4.2), a natural product, has 


















                            (4.1)                                                                (4.2) 
 
The in vitro antiplasmodial activity of aloin (4.3) against the chloroquine-resistant 
Plasmodium falciparum strain has been reported, with an IC50 value of 
107.20 ± 4.14 µg ml-1 3.  Homonataloin (4.4), an aloin analogue, displays more potent 
antiplasmodial activity then aloin (4.3), with an IC50 value of 13.46 ± 1.36 µg ml
-1 3.  
Similarly to artemisinin (4.2), aloin (4.3) and homonataloin (4.4) are naturally occurring 
compounds which display considerable antiplasmodial activity.  Thus the investigation of 
the antiplasmodial activity of derivatives of aloin (4.3) and homonataloin (4.4) could prove 
to be extremely valuable and useful from a medicinal perspective. 
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Malaria is a parasitic disease that is caused by the Plasmodium protozoa (single-celled 
parasites), which is mainly transmitted by the female Anopheles mosquito4.  Malaria is 
prevalent throughout Africa, Asia and Latin America5.  There are four species of the 
human malarial parasite: P. falciparum (most deadly), P. vivax, P. malariae and P. ovale6.  
When a victim is bitten by an infected mosquito, the parasites cause an initial 
asymptomatic infection of the liver cells.  After an incubation period of approximately one 
week, the parasites enter the blood stream.  The parasites infect, develop and multiply 
within host erythrocytes.  A small proportion of these parasites develop into the so-called 
gametocytes (sexual stages), which are able to infect a new mosquito host when they are 
taken up with a meal of blood.  The clinical symptoms of malaria are caused exclusively 
by the parasite erythrocytic stages. 
 
Considering this complex life-cycle of the plasmodial parasite, there are many stages that 
need to be considered as targets for therapy.  Thus, it i  now common to take a 
combination of anti-malarial drugs for treatment to combat the different blood stages of the 
parasite life-cycle.  The efficacy of commercial antimalarial drugs such as chloroquine 
(4.1), when used as monotherapies, are quickly decreasing.  There is a growing demand for 
active compounds with a novel mode of action to replace the current ineffective drugs.  For 
thousands of years, plants have been the basis of sophisticated traditional medicine systems 
and more recently, natural products have provided an excellent source of medicinal lead 
compounds.  Quinine (4.5), which is an alkaloid isolated from Cinchona bark, is the most 
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important lead compound against malaria.  Quinine (4.5) was used as a template in the 
creation of chloroquine (4.1) and mefloquine (4.6).  Artemisinin (4.2), which is isolated 
from the Chinese plant Artemisia annua L., has been successfully used against 

















                                                  (4.5)                                         (4.6) 
 
4.2.2 Established Anti-malarial Drugs 
 
4.2.2.1 Chloroquine (4.1) and Mefloquine (4.6)   
 
Chloroquine (4.1), a 4-aminoquinonline, was first synthesized in 1934, but was only used 
in 1946 because it was initially considered to be too toxic1.  Since then, it has turned out to 
be the most important and effective antimalarial comp und and consequently become the 
drug of choice in many programmes aimed at the global eradication of malaria.  A major 
factor promoting the use of chloroquine (4.1) was the low cost required to produce the 
drug.  Today, chloroquine-resistant strains of P. falciparum are common in all endemic 
areas worldwide1.   
 
Mefloquine (4.6) is considered the standard therapeutic alternative for chloroquine-
resistant malaria.  The use of this drug is limited due to the high costs and appearance of 
neuropsychiatric side effects1.   
 
The mode of action of these 4-aminoquinolines is generally accepted to involve the 
interference with the detoxification of free heme, which is generated during the 
degradation of haemoglobin.  Haemoglobin is ingested by the parasite and transported into 
a central food vauole (Fig. 4.1), where it is digested into small peptides.  These peptides 
are required for the parasite for growth and multiplication.  The resulting heme moiety that 
 95 
is released during haemoglobin degradation is potentially toxic to the parasite through an 


















Figure 4.1. Schematic representation of an erythrocyte infected with P. falciparum, 
indicating the subcellular localization of different drug targets1. 
 
4.2.2.2 Artemisinin (4.2)   
 
Artemisinin (4.2) is a sequiterpene trioxane lactone that was firstisolated in 1971.   
Artemisinin (4.2) and its derivatives, dihydroartemisinin (4.7), artemether (4.8), arteether 
(4.9) and artesunate (4.10), represent a new class of antimalarial drugs thatcontain an 
endoperoxide group.  Artemisinin (4.2) on its own has limited therapeutic value, due to its 
low solubility, low bioavailability, short life and neurotoxicity7.  Thus semi-synthetic 
derivatives with better pharmacokinetic properties have been prepared.  These drugs are all 







































(4.9) (4.10)  
 
The artemisinins act faster than any other malarial d ugs, with an approximate parasite and 
fever clearance time of 32 h.  This is substantially quicker than the 2-3 days required for 
the conventional antimalarial drugs to alleviate thsymptoms.  Moreover, the artemisinins 
act against the sexual parasitic stages, which are responsible for the infection of the female 
Anopheles mosquito and consequently for the transmission of the disease.  These drugs 
have a short plasma half-life and treatment is necessary for 5-7 days to fully eliminate the 
parasites1.     
 
The mechanism of action of the artemisinins evidently depends on the peroxide bond 
cleavage after contact with Fe(II) heme inside the food vacuole (Fig. 4.2).  This results in 
the generation of free radicals that can alkylate the heme molecule.  By this action, the 


























Many antibiotics that are known to be antibacterial agents also display antimalarial 
activity.  Their mode of action depends on the fact that the malarial parasites contain an 
unusual plastid-like organelle called an apicoplast1 (see Figure 4.1).  The apicoplast fulfils 
different metabolic processes, such as the synthesis of fatty acids, isoprenoids and 
potentially heme.  Enzymes involved in metabolic functions within the apicoplast are 
encoded by the nuclear genome and are transported t he apicoplast by a specific terminal-
amino sequence.  Doxycycline (4.11) is the most commonly used antibiotic in anti-malari l 
therapy.  It is used either on its own as a prophylactic, or in combination with quinine 
(4.5)/artensuate (4.10) for treatment in cases of chloroquine-resistant parasites.  
Tetracyclines such as doxycycline (4.11) inhibit protein synthesis inside the apicoplast and 
possibly in the mitochondria. 
N
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Due to the structural similarities between doxycyline and aloin (4.3) (and derivatives), it is 
possible that they have comparable biological activities (see Chapter 3).  Thus the potential 
antiplasmodial activity of aloin (4.3) and derivatives was tested. 
 
4.3 Results and Discussion 
 
Aloin (4.3) and derivatives were screened for their possible antiplasmodial activities, using 
chloroquine (4.1) as a reference.  The methodology used for this testing is in section 4.4.  
The IC50 values of aloin (4.3) and derivatives are displayed in table 4.1 below. 
 
Table 4.1. In vitro antiplasmodial activity against P. falciparum (chloroquine-sensitive) 
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0.01782 0.56 4.69 ± 0.32 1 3 Yes 
* Definitions of ‘drug-likeness’ descriptors are given in Section 4.3.1. 
 
Homonataloin (4.4) is approximately 5 times more active than aloin (4.3).  There are 3 
structural differences (Table 4.2) between the two C-glucosides which possibly contribute 
to this difference in antiplasmodial activity.   
 
Table 4.2 Structural differences between aloin (4.3) and homonataloin (4.4). 
 
Carbon Aloin (4.3) Homonataloin (4.4) 
11 CH2OH CH3 
8 OH OCH3 
7 H OH 

























                                       (4.3)                                       (4.4)         
A study carried out by Winter et al. on hydroxy-anthraquinones established the effect that 
the position of the hydroxyl group has on antiplasmodial activity8.  A series of hydroxy and 
polyhydroxy-anthraquinones based on the potent antipl smodial compound rufigallol 
(4.19) (IC50 ≈ 10.5 ng/ml) were assayed.  The results of this structu e-activity study were 
used as a guideline to help explain the differences in antiplasmodial activity between aloin 










Octahydroxy-9,10-anthraquinone (4.20) (IC50 = 800 ng/ml) has hydroxyl groups at C-8/4 
and C-1/8, along with 9- and 10-carbonyl groups which form a chelating moiety, similar to 
that found in aloin (4.3).  Rufigallol (4.19) lacks the hydroxyl groups at C-8/4, but 
maintains the C-2,3,6,7 hydroxyl groups.  These hydroxyl groups, along with the C-1/5-
hydroxy and C-9/10-ketone moieties resemble the structu al make-up of the anthrone part 
of homonataloin (4.4).  Rufigallol (4.19) is 22 times more active against plasmodial 
parasites then octahydroxy-9,10-anthraquinone (4.20).  The only difference between the 
two is that rufigallol (4.19) lacks the hydroxyl groups at C-8/4.  Homonataloin (4.4) has a 
methoxy-group at C-8, which ‘blocks’ the activity of the hydroxyl-group, which is found 
in aloin (4.3).  Rufigallol (4.19), octahydroxy-9,10-anthraquinone (4.20) and homonataloin 
(4.4) contain hydroxyl groups at C-7/3 which possibly plays a role in antiplasmodial 
activity.  The absence of this C-7 hydroxyl group along with the C-8 hydroxyl group in 
aloin (4.3) compared to homonataloin (4.4), have thus been proposed to be the constituents 














Aloe-emodin (4.12) displayed low antiplasmodial activity compared to al in (4.3).  This 
was probably influenced by the poor solubility displayed by aloe-emodin (4.12) in aqueous 
media.  Rheinal (4.13) and nataloe-emodin (4.14) were insoluble in the plasmodial buffer 
medium and therefore could not be tested.  Rhein (4.15) also showed poor antiplasmodial 
activity, despite having high solubility. 
 
The antiplasmodial activity of the amine derivatives of aloe-emodin proved to be among 
the highest of the derivatives.  The order of antiplasmodial activity was: 11-(piperidin-1-
yl)chrysophanol (4.17) > 11-(pyrrolidin-1-yl)chrysophanol (4.16) > 11-(morpholin-1-
yl)chrysophanol (4.18).  This trend was also observed by Stocks et al.9 who synthesized a 
series of short chain chloroquine derivatives, such as (4.21), (4.22) and (4.23), in which the 
diethylamino side chains were replaced by functional groups that were more resistant to 
dealkylation.  This investigation was carried out to increase the half-life of chloroquine 
(4.1), which is extensively metabolized by dealkylation f the side chains7.  It was found 
that the addition of piperidyl (4.21) and pyrrolidyl (4.22) rings to the 4-amino side chain 
resulted in enhanced activity against chloroquine-resistant P. falciparum.  Interestingly, the 
addition of a morphinyl (4.23) ring resulted in a a considerably lower antiplasmodial 
activity than the piperidyl and pyrrolidyl derivatives, suggesting that the lipophilicity of the 













              (4.21)                                      (4.22)                                  (4.23) 
 
4.3.1 ‘Drug-Likeness’ of Aloin (4.3) and Derivatives 
 
As part of this investigation, aloin (4.3) and derivatives were investigated, based on their
structural features, to determine if they could serve as potential medicinal drugs.  The 
parameters of Lipinski’s ‘rule of 5’ were used as a reference for this study.  C. A. Lipinski 
and co-workers at Pfizer studied the data of drug candidates and discovered that there were 
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some reasonably clear cut-offs for oral absorption and general cell permeability10.  They 
consequently constructed the ‘rule of five’ which serves as a tool to define the ‘drug-
likeness’ of a potential drug candidate based on four parameters.  The "rule-of-5" states 
that poor absorption or permeation is more likely when: 
 
1. The LogP is larger than 5. 
2. There are more then 5 hydrogen-bond donors (expressed a  the sum of the OH’s 
and NH’s). 
3. There are more than 10 hydrogen-bond acceptors (expressed as the sum of nitrogen 
and oxygen atoms). 
4. The molecular weight is over 500. 
 
Most of the aloin derivatives satisfy all these criteria, increasing the possibility of their use 
as medicinal drug targets. 
 
The logP value of a compound is the logarithm of its partition coefficient between n-
octanol and water [log(coctanol/cwater)].  This is a well-established measure of the 
compound's hydrophilicity.  Low hydrophilicities and therefore high logP values (> 5.0) 
cause poor absorption or permeation.  The distribution of calculated logP values of more 
than 3000 drugs on the market underlines this fact.
 
Optimizing compounds for high activity on a biological target is generally accompanied by 
increased molecular weights.  However, compounds with higher molecular weights are less 
likely to be absorbed and therefore to ever reach the site of action.  Thus, trying to keep 
molecular weights as low as possible is crucial. 
 
4.3.2 Mechanism of Action of Aloin (4.3) and Derivatives 
 
The antiplasmodial action of aloin (4.3) and derivatives were compared to those of 
doxycycline (4.11) and rufigallol (4.19), which have many structural features in common 
with aloin (4.3) and its derivatives. 
 
In Chapter 3, aloin (4.3) and its derivatives were tested for their MMP-2 and MMP-9 
inhibitory properties, using doxycycline (4.11) as a reference.  Besides being a MMP-
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inhibitor, doxycycline (4.11) is a powerful antimalarial drug. Doxycycline (4.11) has been 
reported to have an IC50 value of 4800 nM (W2 Strain), in comparison to chloroquine (4.1) 
which has an IC50 value of 100 nM.  A mechanism of action of doxycycline was recently 
proposed by Dahl et al11.  Doxycycline (4.11) causes the apicoplast to become 
dysfunctional in progeny parasites.  Late-stage parasites were those most susceptible to 
doxycycline (4.11).  This effect of doxycycline (4.11) is evident in mature parasites from 
the second generation, which did not rupture to release viable merozoites. 
 
The amine derivatives of aloe-emodin, i.e. 11-(piperidin-1-yl)chrysophanol (4.17),          
11-(pyrrolidin-1-yl)chrysophanol (4.16) and 11-(morpholin-1-yl)chrysophanol (4.18) 
resemble the pharmacophore profile of doxycycline (4.11) very closely, and thus could 
share its mechanism of action.  Comparing the structu es of doxycycline (4.11) and 11-
(piperidin-1-yl)chrysophanol (4.17), it can be seen that they both share many common 
structural features.  Firstly, they both contain the same chelating moiety A, i.e. the C-11/13 
hydroxy-C-12 ketone combination in doxycycline (4.11) and C-1/8 hydroxyl-C-9 ketone 
combination in 11-(piperidin-1-yl)chrysophanol (4.17).  This chelating feature is common 
to all the aloin derivatives.  Secondly, doxycycline has a tertiary amine nitrogen atom 3-
carbon atoms away from the C-13 hydroxyl group (B).  This structural feature is also found 
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                                    (4.11)                                     (4.17) 
 
The antimalarial action of rufigallol (4.19) is postulated to involve an iron chelation 
mechanism, similar to that of desferroxamine (desferal) (4.24)8.   The antimalarial effect of 
desferroxamine (4.24) has been shown to involve chelation of iron, which required for 
cellular metabolism and DNA synthesis of the parasite.  Desferroxamine has also been 























Aloin (4.3) and its derivatives displayed fairly good activity against the chloroquine-
sensitive strain of P. falciparum. The two amine derivatives, i.e. 11-(pyrrodin-1-
yl)chrysophanol (4.16) and 11-piperidin-1-yl)chrysophanol (4.17) showed the best 
antiplasmodial activities. It was noteworthy to discover that homonataloin (4.4) was fives 
times more active against the Plasmodium parasites than aloin (4.3). Thus it can be 
concluded that aloin (4.3) and possibly homonataloin (4.4) can serve as lead compounds in 




Aloin (4.3) and its derivatives were sent to the Division of Pharmacology at the University 
of Cape Town for the screening of in vitro plasmodial activity.  The methodology that was 
used at this institute was as follows: 
 
The test compounds were tested in duplicate on one occasion against chloroquine-sensitive 
(CQS) strain of P. falciparum (D10).  Continuous in vitro cultures of asexual erythrocyte 
stages of P. falciparum were maintained using a modified method of Trager and Jensen12.  
Quantitative assessment of antiplasmodial activity n vitro was determined via the parasite 
lactate dehydrogenase assay using a modified method described by Makler13.   
 
The samples were prepared as 2 mg/ml stock solutions in 10% DMSO or 10% methanol 
and were sonicated to enhance solubility.  Samples w re tested as a suspension if not 
completely dissolved.  Stock solutions were stored at -20 ºC.  Further dilutions were 
prepared on the day of the experiment.  Chloroquine (4.1) was used as the reference drug 
 105 
in all experiments.  A full dose-response was performed for all compounds to determine 
the concentration inhibiting 50% of parasite growth (IC50 value).  Test samples were tested 
at a starting concentration of 100 µg/ml, which was then serially diluted 2-fold in complete 
medium to give 10 concentrations; with the lowest concentration being 0.2 µg/ml.  The 
same dilution technique was used for all samples.  Chloroquine (4.1) was tested at a 
starting concentration of 100 ng/ml.  The highest concentration of solvent to which the 
parasites were exposed had no measurable effect on the parasite viability (data not shown).  
The IC50-values were obtained using a non-linear dose-response curve fitting analysis via 
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Aloe marlothii is known to be a rich source of phenolic compounds, especially aloin 
(5.1).   Aloin (5.1) was isolated from the A. marlothii leaf exudate by both conventional 
(column chromatography) and novel (calcium-salt preci itation) methods.  Aloin (5.1), 
being unstable in solution, was chemically transformed into a more stable derivative, i.e. 
aloe-emodin (5.2) which lacks the sugar moiety.  Aloe-emodin (5.2) was then 
transformed into several derivatives with potentially useful biological activities.  Aloin 
(5.1) and derivatives were tested for (i) their potential as MMP-2 and MMP-9 inhibitors 
and for (ii) their potential antiplasmodial activity against a strain of chloroquine-sensitive 
Plasmodium falciparum parasites.  Doxycyline (5.3), a clinical drug that is structurally 
similar to aloin and derivatives, was used as a reference compound in both of the 
biological assays.  11-(Piperidin-1-yl)chrysophanol (5.4) and 11-(morpholin-1-
yl)chrysophanol (5.5) proved to be the most potent selective MMP-2 inhibitors.  11-
(Piperidin-1-yl)chrysophanol (5.4) was also found to be the most potent against P. 
falciparum parasite, along with 11-(pyrrolidin-1-yl)chrysophanol (5.6).  Aloin (5.1) has 
been thus shown to be a cheap, easily obtainable starting material that can be transformed 
























             (5.4)                                        (5.5)                                             (5.6) 
 
5.2 Future Work 
 
The results obtained from both of the biochemical assays provide useful information for 
the development of more potent drugs.  With regard to the MMP-inhibitory studies, 6-
membered rings, with varied substituents (5.7), may prove to be highly active against 
MMP-2. The incorporation of even larger rings or more highly substituted rings should 
also be examined. Molecular modelling would also be a powerful tool in understanding 
the mechanism of the compounds’  inhibitory action, thus aiding the process of designing 





R = substituted 6-membered nitrogen-containing ring 
                                   (5.7) 
  
Based on the results obtained from the antiplasmodial studies, it was established that the 
aloin (5.1) analogue, homonataloin (5.8), contained a structural motif that was more 
potent towards the P. falciparum parasites then aloin (5.1). Thus, homonataloin (5.8), 
which can be isolated from specific A. marlothii plants, would serve as a far more useful 
starting compound in the preparation of antiplasmodial rugs.  The synthesis of 























































Figure 5.1. Potential antiplasmodial compounds derived from hoonataloin (5.8). 
 
Compound (5.9) contains a quinoline moeity, based on chloroquine, which is known to 
have antiplasmodial activity. 
 
The toxicity of aloin and derivatives would also need to be investigated, to clearly 







Plate 1a:   1H NMR Spectrum of aloin A (2.1) in MeOH-d4 
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Plate 3c: DEPT NMR Spectrum of aloesin (2.3) in MeOH-d4 
 
 




































































































































































































































Plate 4a: 1H NMR Spectrum of homonataloin (2.4) in DMSO-d6 
 
A: -  isomer 


































































































Plate 4b: 13C NMR Spectrum of homonataloin (2.4) in DMSO-d6 
 
A: -isomer 









































































































































































































































































































































































































































































































































































































































































































































































































Plate 6b: 13C NMR Spectrum of nataloe-emodin (2.28) in DMSO-d6 





































































































































































































































































































































































































































































































































































































Plate 8a: 1H NMR Spectrum of IBX (2.30) in DMSO-d6 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Plate 13f: HMBC NMR Spectrum of 11-(morpholin-1-yl)chrysophanol (2.36) in DMSO-d6 
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